

NACC UNIFORM DATA SET

Initial Visit Packet

UDSv4.0, January 2025

Copyright© 2006, 2008, 2015, 2017, 2020, 2025 University of Washington. Created and published by the ADRC Clinical Task Force (Allan Levey, MD, PhD, Chair) and the National Alzheimer's Coordinating Center (Walter A. Kukull, PhD, Director). All rights reserved.

This publication was funded by the National Institutes of Health through the National Institute on Aging (Cooperative Agreement U24 AG072122).

Revisions made to this Initial Visit Packet (IVP) since release (December 2024)

Date yyyy-mm-dd	Description	Form(s) affected	Question(s) affected
2024-12-18	Fixed numbering error on A1a, subquestions of Q37.	A1a	Q37a1 - Q37a15
2025-02-14	Changed informative missing codes (88 and 99) to 888 and 999 throughout Section 7: Menstrual and Reproductive Health	A5-D2	Q7a-Q7b Q7d1-Q7d3 Q7e1-Q7e3
2025-02-14	Fixed typos on B4 and A5/D2	B4, A5-D2	N/A

Table of Contents	
Form A1: Participant Demographics	4
Form A1a: Social Determinants of Health	12
Form A2: Co-Participant Demographics	18
Form A3: Participant Family History	19
Form A4: Participant Medications	22
Form A4a: ADRD-Specific Treatments	24
Form A5-D2: Participant Health History/Clinician-assessed Medical Conditions	26
Form B1: EVALUATION FORM - Vital Signs and Anthropometrics	33
Form B3: Unified Parkinson's Disease Rating Scale (UPDRS) - Motor Exam	35
Form B4: CDR Dementia Staging Instrument plus NACC FTLD Behavior & Language Domains (CDR Plus NACC FTLD)	39
Form B5: BEHAVIORAL ASSESSMENT - Neuropsychiatric Inventory Questionnaire (NPI-Q)	41
Form B6: BEHAVIORAL ASSESSMENT - Geriatric Depression Scale (GDS)	42
Form B7: FUNCTIONAL ASSESSMENT - NACC Functional Assessment Scale (FAS)	43
Form B8: EVALUATION FORM - Neurological Examination Findings	44
Form B9: Clinician Judgment of Symptoms	47
Form C2: Neuropsychological Battery Scores	52
Form C2T: Neuropsychological Battery Scores for T-cog	56
Form D1a: Clinical Syndrome	60
Form D1b: Etiological Diagnosis and Biomarker Support	65

INITIAL VISIT PACKET

UNIFORM DATA SET (UDS) VERSION 4.0



Form A1: Participant Demographics

ADRC:	PTID:	Form date:	/ Visit #:_	initials:
Language:	Administration:	Mode:	Key (remote reason):	1=Too cognitively impaired
□1 English	☐ 1 Self-administered	□ 1 In-person		2=Too physically impaired
☐2 Spanish	☐2 Staff-administered	☐ 2 Remote (reason):		3=Homebound/nursing home
		□1 Telephone □2 Video		4=Refused in-person visit
		☐ 3 Mail ☐ 4 Electronic (e.g., email)		5=Other

INSTRUCTIONS: This form may be completed by intake interviewer based on ADRC scheduling records, participant interview, medical records, and proxy co-participant report (according to what is deemed to be the most reliable source of information, except as indicated for specific questions that may be based on the participants perceptions and experience which only they can provide accurate information for). This information can be collected by mail-in survey, electronic capture (web-based), phone or video interview, or during the in-person visit to accommodate and lessen participant visit burden. For additional clarification and examples, see the **UDS Coding Guidebook, Form A1.** Check only one box per question unless otherwise specified.

1. What is your month and year of birth (MM / YYYY)?			
2. In which country or region did you spend most of your childhood? (Enter three character code from Appendix 1) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3a.	Secti	on 1 — Demographics	
2. In which country or region did you spend most of your childhood? (Enter three character code from Appendix 1) 3. What is your race and/or ethnicity? (Check all that apply and enter additional details in the space below.) 3a. \[\] A American Indian or Alaska Native (AIAN) (SPECIFY, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Barrow Inpita Traditional Government, Nome Eskimo Community, Aztec, Maya): 3b. \[\] 1 Asian Indian 3b1. \[\] 1 Chinese 3b2. \[\] 1 Asian Indian 3b3. \[\] 1 Filipino 3b4. \[\] 1 Vietnamese 3b5. \[\] 1 Japanese 3b7. \[\] 1 Other (SPECIFY, for example, Pakistani, Hmong, Afgham): 3c1. \[\] 1 Black or African American 3c2. \[\] 1 Jamaican 3c3. \[\] 1 Haitian 3c4. \[\] 1 Nigerian 3c5. \[\] 1 Ethiopian 3c6. \[\] 1 Somali 3c7. \[\] 1 Other (SPECIFY, for example, Chaukese, Palauan, Tahitian): 3d1. \[\] 1 Hexican 3d2. \[\] 1 Puerto Rican 3d3. \[\] 5 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, French, Swedish, Norwegian): 3h. \[\] 1 Other (SPECIFY, for example, Colombian,	1.	What is your month and year of birth (MM / YYYY)?	/
3a.	2.	most of your childhood?	
nonauran, spaniara K	3.	What is your race and/or ethnicity? (Check all that apply and ent 3a.	3e. 1 Middle Eastern or North African 3e1. 1 Lebanese 3e2. 1 Iranian 3e3. 1 Egyptian 3e4. 1 Syrian 3e5. 1 Iraqi 3e6. 1 Israeli 3e7. 1 Other (SPECIFY, for example, Moroccan, Yemeni, Kurdish): 3f. 1 Native Hawaiian or Pacific Islander 3f1. 1 Native Hawaiian 3f2. 1 Samoan 3f3. 1 Chamorro 3f4. 1 Tongan 3f5. 1 Fijian 3f6. 1 Marshallese 3f7. 1 Other (SPECIFY, for example, Chuukese, Palauan, Tahitian): 3g. 1 White 3g1. 1 English 3g2. 1 German 3g3. 1 Irish 3g4. 1 Italian 3g5. 1 Polish 3g6. 1 Scottish 3g7. 1 Other (SPECIFY, for example, French, Swedish, Norwegian):

Particip	ant ID: Form dat	e: / /	Visit #:
Secti	on 1 — Demographics		continued
will be yourse	xt four questions ask about your gender identit used to help us improve health, well-being, an If as being a man, woman, or a different gender ution, and it can change over time.	d quality of care. By gender identity, v	we mean the inner sense that you have of
4.	Which term(s) best describes your current gender identity? (Check all that apply)	4a. 1 Man 4b. 1 Woman 4c. 1 Transgender man 4d. 1 Transgender woman 4e. 1 Non-binary/genderqueer 4f. 1 Two-Spirit (if you are AIAN) 4g. 1 I use a different term (SPECI 4h. 1 Don't know 4i. 1 Prefer not to answer	FY):
5.	What sex were you assigned at birth; on your o	original birth certificate?	☐ 1 Male ☐ 2 Female ☐ 9 Don't know ☐ 8 Prefer not to answer
6.	Have you ever been diagnosed by a medical d with an intersex condition or a "Difference of S born with (or developed naturally in puberty) or chromosomal patterns that do not fit stand	sex Development (DSD)" or were you genitals, reproductive organs, and/	o No 1 Yes 9 Don't know 8 Prefer not to answer
7.	Which term(s) best describes your sexual orientation? (Check all that apply)	7a. 1 Lesbian or gay 7b. 1 Straight/heterosexual 7c. 1 Bisexual 7d. 1 Two-Spirit (if you are AIAN) 7e. 1 I use a different term (SPECI 7f. 1 Don't know 7g. 1 Prefer not to answer	FY):
8.	What is your primary language? (Primary language is defined as the predominan your life. Please take into consideration first lang use.)		1 English 2 Spanish 3 Chinese dialect 8 Other (SPECIFY):
9.	Are you left- or right-handed (for example, whi writing)?	ch hand would normally be used for	1 Left-handed 2 Right-handed 3 Ambidextrous 9 Don't know
10a.	How many years of education have you comp	leted? (99 = Unknown)	
10b.	What is your highest achieved level of educati	on?	1 Less than high school 2 High school or GED 3 Some college 4 Bachelor's degree 5 Master's degree 6 Doctorate 9 Don't know

4 Separated
5 Never married (or marriage was annulled)
6 Living as married / domestic partner
9 Don't know

1 Married
2 Widowed
3 Divorced

11. What is your <u>current</u> marital status?

Secti	on 1 — Demographics		continued
12.	What is your living situation?	1 Live alone 2 Live with one other person: a sp 3 Live with one other person: a re 4 Live with caregiver who is not s 5 Live with a group (related or not 6 Live in group home (e.g., assisted	lative, friend, or roommate pouse/partner, relative, or friend <i>related</i>) in a private residence
13.	What is your primary type of residence?	2 Retirement community or indep 3 Assisted living, adult family hon 4 Skilled nursing facility, nursing I	ne, or boarding home nome, hospital, or hospice g with others, in a hotel, in a shelter, living
14.	What are the first three digits of the ZIP code of (For example, if your ZIP code is 12345, enter 123.)	f your primary residence?	(If unknown, leave blank)
15.	Have you ever served on active duty in the U.S National Guard?	. Armed Forces, military Reserves, or	☐ 0 No (IF NO, SKIP TO QUESTION 17) ☐ 1 Yes ☐ 9 Don't know
16.	Have you ever obtained medical care or prescr (VA) facility?	□ 0 No □ 1 Yes □ 9 Don't know	
17.	How much time in total do you spend each we physically strenuous activities that cause increasing at least 10 minutes continuously? (Include activity at work, traveling to and from precedinal activities.)	1 None 2 1 hour or less 3 2.5 hours or less 4 More than 2.5 hours 8 Prefer not to answer 9 Don't know	
Secti	on 2 — Memory		
18.	Do you feel like your memory is becoming wor	rse?	□ 0 No □ 1 Yes, but this does not worry me □ 2 Yes, and this worries me □ 9 Don't know / Prefer not to answer
19.	About how often do you have trouble rememb	☐ 1 Never ☐ 2 Rarely ☐ 3 Sometimes ☐ 4 Often ☐ 5 Very often ☐ 9 Don't know / Prefer not to answer	
20.	Compared to 10 years ago, would you say that worse, the same, a little better, or much better	☐ 1 Much better ☐ 2 A little better ☐ 3 The same ☐ 4 A little worse ☐ 5 Much worse ☐ 9 Don't know / Prefer not to answer	

Form date: ____ / ___ / ___ __ __ __

Participant ID:

For A	DRC use only:	
The r	ext two questions use t	he Area Deprivation Index (ADI) lookup at https://www.neighborhoodatlas.medicine.wisc.edu/mapping . Enter the participant's state and full address.
21.	ADI state-only decile:	(If unknown, leave blank
22.	ADI national percentile	:: (If unknown, leave blank
23.	Participant's primary o (Enter three number code t	ccupation throughout their working life from Appendix 2): (If unknown, leave blank
24.	ADRC enrollment type:	☐ 1 Participant is supported primarily by ADRC funding (Clinical Core, Satellite Core, or other ADRC Core or project) ☐ 2 Participant is supported primarily by a non-ADRC study (e.g., R01, including non-ADRC grants supporting FTLD Module participation)
25.	Principal referral source	□ 1 Self □ 2 Non-professional personal contact who is not a current or previous ADRC participant (e.g., spouse/partner, relative, friend, coworker) □ 3 Current or previous ADRC participant (END FORM HERE) □ 4 ADRC clinician, staff, or investigator (END FORM HERE) □ 5 Non-ADRC healthcare professional (e.g., clinician, nurse, social worker) (END FORM HERE) □ 6 Other research study clinician/staff/investigator (non-ADRC; e.g., ADNI, Women's Health Initiative, LEADS, ALL-FTD) (END FORM HERE) □ 8 Other (SPECIFY): (END FORM HERE) □ 9 Unknown (END FORM HERE)
26.	If the referral source was self-referral or a nonprofessional contact, how did the referral source learn of the ADRC? (choose most relevant option)	Community outreach event 1 ADRC sponsored event 2 Event sponsored by an external organization (e.g., Alzheimer's Association event, institution sponsored venue, community health fair, professional conference) Other ADRC outreach 3 Newsletter (mailed or digital) 4 Study flyer/brochure (mailed or digital) 5 Center website 6 Center social media (SPECIFY):

Other registries, websites, organizations, or media promotions

8 Website (SPECIFY):

9 Media (SPECIFY):

10 Registry (SPECIFY):

88 Other (SPECIFY):

99 Unknown

Form date: ____ / ___ / ___ __ __ __

Visit #:

Participant ID:

Appendix 1: Birth Country*							
Code	Country	Code	Country	Code	Country		
AFG	Afghanistan	CHN	China	GRL	Greenland		
XQZ	Akrotiri	CXR	Christmas Island	GRD	Grenada		
ALB	Albania	CPT	Clipperton Island	GLP	Guadeloupe		
DZA	Algeria	CCK	Cocos (Keeling) Islands	GUM	Guam		
ASM	American Samoa	COL	Colombia	AX2	Guantanamo Bay Naval Base		
AND	Andorra	COM	Comoros	GTM	Guatemala		
AGO	Angola	COG	Congo (Brazzaville)	GGY	Guernsey		
AIA	Anguilla	COD	Congo (Kinshasa)	GIN	Guinea		
ATA	Antarctica	COK	Cook Islands	GNB	Guinea-Bissau		
ATG	Antigua and Barbuda	XCS	Coral Sea Islands	GUY	Guyana		
ARG	Argentina	CRI	Costa Rica	HTI	Haiti		
ARM	Armenia	CIV	Cote D'Ivoire	HMD	Heard Island and McDonald Islands		
ABW	Aruba	HRV	Croatia	HND	Honduras		
XAC	Ashmore and Cartier Islands	CUB	Cuba	HKG	Hong Kong		
AUS	Australia	CUW	Curacao	XHO	Howland Island		
AUT	Austria	CYP	Cyprus	HUN	Hungary		
AZE	Azerbaijan	CZE	Czechia	ISL	Iceland		
BHS	The Bahamas	DNK	Denmark	IND	India		
BHR	Bahrain	XXD	Dhekelia	IDN	Indonesia		
XBK	Baker Island	DGA	Diego Garcia	IRN	Iran		
BGD	Bangladesh	DJI	Djibouti	IRQ	Iraq		
BRB	Barbados	DMA	Dominica	IRL	Ireland		
XBI	Bassas da India	DOM	Dominican Republic	IMN	Isle of Man		
BLR	Belarus	ECU	Ecuador	ISR	Israel		
BEL	Belgium	EGY	Egypt	ITA	Italy		
BLZ	Belize	SLV	El Salvador	JAM	Jamaica		
BEN	Benin	GNQ	Equatorial Guinea	XJM	Jan Mayen		
BMU	Bermuda	ERI	Eritrea	JPN	Japan		
BTN	Bhutan	EST	Estonia	XJV	Jarvis Island		
BOL	Bolivia	SWZ	Eswatini	JEY	Jersey		
BES	Bonaire, Sint Eustatius, and Saba	ETH	Ethiopia	XJA	Johnston Atoll		
BIH	Bosnia and Herzegovina	XEU	Europa Island	JOR	Jordan		
BWA	Boundaland	FLK	Falkland Islands (Islas Malvinas)	XJN	Juan de Nova Island		
BVT	Bouvet Island	FRO	Faroe Islands	KAZ	Kazakhstan		
BRA IOT	Brazil British Indian Ocean Territory	FJI FIN	Fiji Finland	KEN XKR	Kenya Kingman Reef		
BRN	Brunei	FRA		KIR	Kiribati		
BGR	Bulgaria	GUF	France French Guiana	PRK	North Korea		
BFA	Burkina Faso	PYF	French Polynesia	KOR	South Korea		
MMR	Burma	ATF	French Southern and Antarctic Lands	XKS	Kosovo		
BDI	Burundi	GAB	Gabon	KWT	Kuwait		
CPV	Cabo Verde	GMB	The Gambia	KGZ	Kyrgyzstan		
KHM	Cambodia	XGZ	Gaza Strip	LAO	Laos		
CMR	Cameroon	GEO	Georgia	LVA	Latvia		
CAN	Canada	DEU	Germany	LBN	Lebanon		
CYM	Cayman Islands	GHA	Ghana	LSO	Lesotho		
CAF	Central African Republic	GIB	Gibraltar	LBR	Liberia		
TCD	Chad	XGL	Glorioso Islands	LBY	Libya		
CHL	Chile	GRC	Greece	LIE	Liechtenstein		

^{*}Codes were developed by the U.S. Government and endorsed by the Federal Geographic Data Committee. https://www.fgdc.gov/standards/news/GENC

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Uthuania PRY Paraguay TWN Taiwan A Taiwan PER Peru TJK Tajikistan PER Peru TJK Tajikistan TJK Tajikistan PRT Portugal TJK Tajikistan TLS Timor-Leste TJK Tajikistan TLS Timor-Leste TJK Tajikistan TLS Timor-Leste TJK Tajikistan TLS Timor-Leste TJK Malawi POL Poland TLS TIMOR		ndix 1: Birth Country*				
C. Macau	Code	Country	Code	Country	Code	Country
AC Macau PHL Philippines TZA Tanzania Madagascar PCN Pitcairn Islands THA Thailand Thailand POL Malawi POL Poland TLS Timor-Leste Too Malaysia PRT Portugal TGO Togo Togo Togo Malaysia PRT Portugal TGO Togo Togo Togo Maldives PRI Puerto Rico TKL Tokelau TON Tonga Trinidad and Tobage Malaysia REU Reunion TTO Trinidad and Tobage Malaysia ROU Romania TTO Trinidad and Tobage Martinique RUS Russia TUN Tunisia Tunkey Malaysia ROU Romania TUN Tunisia TUN Tunisia TUN Tunisia Mauritania RWA Rwanda TUN Tunkey SMS Mauritius BLM Saint Barthelemy TKM Turkmenistan TUR Mayotte SHN Saint Barthelemy TKM Turkmenistan TUR Turkey SMN Saint Mitts and Nevis TUV Tuvalu UGA Uganda WSM Rederated States of Micronesia LCA Saint Lucia UGA Uganda WSM Midway Islands MAF Saint Martin UKR Ukraine ARE United Krabe Emirate Moldova SPM Saint Pierre and Miquelon ARE United Krabe Emirate Montenegro SMR Saint Martin UKR Ukraine Montenegro SMR San Marino AX1 Unknown RM Montenegro SMR San Marino AX1 Unknown Wish Samoa USA Unknown RM Montenegro SMR San Marino AX1 Unknown Wish Samoa USA Unknown RM Montenegro SMR San Marino AX1 Unknown Wish Samoa USA Unknown RM Montenegro SMR San Marino AX1 Unknown Wish Montenegro AX1 Unknown Wish Montenegro AX1 Unknown Wish Montenegro AX1 Unknown Wish Montenegr	_TU	Lithuania	PRY	Paraguay	TWN	Taiwan
No. Madagascar PCN Pitcairn Islands THA Thailand Timor-Leste Timor-Leste Togo Malaysia PRT Portugal TGO Togo Maldives PRI Puerto Rico TKL Tokelau T	LUX	Luxembourg	PER		TJK	Tajikistan
Malawi POL Poland TLS Timor-Leste Tortugal TGO Togo Malaysia PRT Portugal TGO Togo Togo Maldives PRI Puerto Rico TKL Tokelau TGO Togo Maldives PRI Puerto Rico TKL Tokelau TGO Togo Trinidad and Tobagg Timor Malta REU Reunion TTO Trinidad and Tobagg Timor Malta REU Reunion TTO Trinidad and Tobagg Timor Martinique RUS Russia TUN Tunisia Turkey Rushidilisand ROU Romania TUN Tunisia Turkey Rushidilisand Rou Rowanda TUN Tunisia Turkey SMA Ravirtania RWA Ravanda TUN Tunisia Turkey SMA Turkey SMA Turkey SMA Turkey SMN Saint Barthelemy TKM Turkemsistan TGA Turks and Caicos Isla Tristan da Cunha Tristan Tristan da Cunha Tristan Tris	MAC	Macau	PHL	Philippines	TZA	Tanzania
Malaysia PRT Portugal TGO Togo Tokelau Maldives PRI Puerto Ricco TKL Tokelau Tokel	ИDG	Madagascar	PCN	Pitcairn Islands	THA	Thailand
Maldives PRI Puerto Rico TKL Tokelau Mali QAT Qatar TON Tonga T Malta REU Reunion TTO Trinidad and Tobage RU Marshall Islands ROU Romania XTR Tromelin Island RU Russia TUN Tunisia RU Russia TUN Tunisia RU Russia TUN Tunisia RU Mauritania RWA Rwanda TUR Turkey RUS Mauritius BLM Saint Barthelemy TKM Turkmenistan TTM Auritania RWA Rwanda TUR Turkey RUS Mauritius RUM Saint Barthelemy TKM Turkmenistan TCA Turks and Caicos Isla Tristan da Cunha TCA Turks and Caicos Isla Tristan da Cunha TUR Turkand RUS Mayotte ShN Saint Kitts and Nevis TUV Tuvalu RUM Federated States of Micronesia LCA Saint Lucia UGA Uganda RUM Midway Islands MAF Saint Martin UKR UKraine RUM Midway Islands MAF Saint Martin UKR UKraine RUM Midway Islands SPM Saint Pierre and Miquelon ARE United Arab Emirate RUM Monaco VCT Saint Vincent and the Grenadines RUM Mongolia WSM Samoa USA United States RUM Montenegro SMR San Marino AX1 Unknown RUM Montenegro SAU Saudi Arabia UZB Uzbekistan RUM Morocco SAU Saudi Arabia UZB Uzbekistan RUM Morocco SAU Saudi Arabia UZB Uzbekistan RUM Mamibia SRB Serbia UT Vanuatu RUM Nawassa Island SLE Sierra Leone VNM Vietnam RUM Nawassa Island SLE Sierra Leone VNM Vietnam RUM Nawassa Island SVK Slovakia XWK Wake Island RUM Nawassa Island SVR Slovakia XWK Wake Island RUM Nigeria ZAF South Africa YEM Yemen RUM Nordel Island SSD South Sudan ZWE Zimbabwe RUM Norway LKA Sri Lanka SUR Suriname RUM Palau XSV Svalbard LA Palmya Atoll SWE Sweden LA Palmya Atoll SW	ΛWI	Malawi	POL	Poland	TLS	Timor-Leste
I Mali REU Reunion TON Tonga II Malta REU Reunion TTO Trinidad and Tobage; II Marshall Islands ROU Romania XTR Tromelin Island IV Marshall Islands ROU Romania XTR Tromelin Island IV Mauritania RWA Rwanda TUN Tunisia IV Mauritania RWA Rwanda TUN Tunisia IV Mauritania RWA Rwanda TUR Turkey IV Tuvalu Turkey IV Tuvalu Usand Caint Micronesia LCA Saint Helena, Ascension, and TCA Turks and Caicos Isla Tristan da Cunha IV Midway Islands MAF Saint Martin UKR Ukraine IV Midway Islands MAF Saint Martin UKR Ukraine IV Moldova SPM Saint Pierre and Miquelon UKR Ukraine IV Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom IV Montenegro SMR San Marino AX1 Unknown IV Montserrat STP Sao Tome and Principe URY Uruguay IV Moxambique SEN Senegal VUT Vanuatu IV Mauru SYC Seychelles VEN Venezuela IV Nauru SYC Seychelles VEN Venezuela IV Naurau SYC Seychelles VEN Venezuela IV Seychelles VEN Venezue	ΛYS	Malaysia	PRT	Portugal	TGO	Togo
T. Malta REU Reunion TTO Trinidad and Tobage RU Marshall Islands ROU Romania XTR Tromelin Island O Martinique RUS RUS RUSsia TUN Tunisia TUN Tunisia RWA Rwanda TUR Turksey TUN Tunisia TUR REVISION TUNISIA T	ЛDV	Maldives	PRI	Puerto Rico	TKL	Tokelau
ROU Romania XTR Tromelin Island V Americique RUS Russia TUN Tunisia TUN Tunisia TUN Mauritania RWA Rwanda TUR Turkey Sint Mauritania RWA Rwanda Trustan da Cunha Tristan da Cunha Tristan da Cunha URA UGA Uganda UGA Uganda UGA Uganda UGA Ulariania Maldova SpM Saint Martin UKR Ukraine Wiki Midway Islands MAF Saint Martin UKR Ukraine Wiki Midway Islands MAF Saint Martin UKR Ukraine Sint Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom GBR United Kingdom GBR United Kingdom WSM Samoa USA United Kingdom WSM Wontserat STP Sao Tome and Principe URY Uruguay URY Uruguay WSM Monocco SAU Saudi Arabia UZB Uzbekistan UZB Uzbekistan WSM Namibia SRB Serbia WAT Vatican City UNIT Vanuatu SYC Seychelles VEN Venezuela VAN Nauru SYC Seychelles VEN Venezuela VAN Nauru SYC Seychelles VEN Venezuela UNIT Vanuatu SYC Seychelles VEN Venezuela UNIT Vanuatu SYC Sophia WSM With Marten WR US. Virgin Islands UNIT Mauritania SRB Solowania SYM Slovakia XWK Wake Island UNIT Williand SYM Slovakia XWK Wake Island SYM Slovakia XWK Wake Island SYN Slovakia XWK Wake Island SYN Slovakia XWK Wake Island SYN Slovakia SYM Wake Island SYN Slovakia SYM Swesten South Africa YEM Yemen Son South Sudan Syn Slovakia SYM Swesten South Sudan Syn Slovakia SYM Swesten Syn Slovakia SYM Swesten Syn Slovakia SYM Swesten Syn Slovakia SYM Swesten Syn South Sudan Syn Sudan Syn South Sweden Syn South Sweden Sweden Sweden Sweden Sweden Sw	ЛLI	Mali	QAT	Qatar	TON	Tonga
Q Martinique RUS Russia TUN Tunisia IT Mauritania RWA Rwanda TUR Turkey IS Mauritius BLM Saint Barthelemy TKM Turks and Caicos Isla IT Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha TCA Turks and Caicos Isla IV Midova SHN Saint Kitts and Nevis TUV Tuvalu IV Midway Islands MAF Saint Martin UKR Ukraine IV Midway Islands MAF Saint Martin UKR Ukraine IV Moldova SPM Saint Pierre and Miquelon ARE United Arab Emirate IV Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom IV Monaco SMR San Marino AX1 Unknown IV Montenegro SMR San Marino AX1 Unknown IV Morocco SAU Saudi Arabia UZB Uzbekistan IV Mozambique SEN Senegal VUT Vanuatu IV Navassa Island SLE Sierra Leone VNM VAT Vatican City IV	ИLT	Malta	REU	Reunion	TTO	Trinidad and Tobago
RT Mauritania RWA Rwanda TUR Turkey SM Mauritius BLM Saint Barthelemy TKM Turkmenistan TAM Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha X Mexico KNA Saint Kitts and Nevis TUV Tuvalu W Federated States of Micronesia LCA Saint Lucia UGA Uganda W Midway Islands MAF Saint Martin UKR Ukraine A Moldova SPM Saint Pierre and Miquelon ARE United Arab Emirate GM Monaco VCT Saint Vincent and the Grenadines IE Montenegro SMR San Marino AX1 Unknown IE Montenegro SMR San Marino AX1 Unknown W Morocco SAU Saudi Arabia UZB Uzbekistan DZ Mozambique SEN Senegal VUT Vanuatu M Namibia SRB Serbia VAT Vatican City UN Nauru SYC Seychelles VEN Venezuela LN Neval SGP Singapore VGB British Virgin Islands LN Nepal SGP Singapore VGB British Virgin Islands LN Nepal SGP Singapore VGB British Virgin Islands LN New Caledonia SVK Slovakia XWK Wake Island LN New Caledonia SVK Slovakia XWK Wake Island LN New Caeland SVN Slovenia ESH Western Sahara LN New Caeland SSD South Georgia and South Sambius LN Northern Mariana Islands XSP Spain Northern Mariana Islands XSV Svalbard LN Palawra Atoll SWE Sweden N Palawra Atoll SWE Sweden LP Nanma CHE Switzerland	۱HL	Marshall Islands	ROU	Romania	XTR	Tromelin Island
Mayotte	ЛTQ	Martinique	RUS	Russia	TUN	Tunisia
Mayotte	ИRT	Mauritania	RWA	Rwanda	TUR	Turkey
TT Mayotte SHN Saint Helena, Ascension, and Tristan da Cunha X Mexico KNA Saint Kitts and Nevis TUV Tuvalu M Federated States of Micronesia LCA Saint Lucia UGA Uganda W Midway Islands MAF Saint Martin UKR Ukraine ADA Moldova SPM Saint Pierre and Miquelon ARE United Arab Emirate TO Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom WSM Samoa USA United States IE Montenegro SMR San Marino AX1 Unknown R Montserrat STP Sao Tome and Principe URY Uruguay WR Morocco SAU Saudi Arabia UZB Uzbekistan DY Mozambique SEN Senegal VUT Vanuatu M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela VI Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SYK Slovakia XWK Wake Island L New Zealand SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Venen J Niue SGS South Sudan ZWE Zimbabwe KN Northern Mariana Islands XSP Sprati Islands KN Northern Mariana Islands XSP Spraty Islands KN Northern Mariana Islands XSP Spraty Islands KN Northern Mariana Islands XSV Svalbard KN Palau XSV Svalbard L Palmyra Atoll SWE Sweden CHE Switzerland	ИUS	Mauritius	BLM	Saint Barthelemy	TKM	· ·
M Federated States of Micronesia LCA Saint Lucia UGA Uganda Way Midway Islands MAF Saint Martin UKR Ukraine UKR UKR UKRAINE UKR UKR UKRAINE UKR	ЛҮТ	Mayotte		Saint Helena, Ascension, and	TCA	Turks and Caicos Islands
M Federated States of Micronesia LCA Saint Lucia UGA Uganda Way Midway Islands MAF Saint Martin UKR Ukraine UKR UKR UKRAINE UKR UKR UKRAINE UKR	ИΕХ	Mexico	KNA		TUV	Tuvalu
My Midway Islands MAF Saint Martin UKR Ukraine Moldova SPM Saint Pierre and Miquelon ARE United Arab Emirate Monaco VCT Saint Vincent and the Grenadines GR United Kingdom USA United States United States United States United States United States Mongolia WSM Samoa USA United States USA United States Montenegro SMR San Marino AX1 Unknown RR Montserrat STP Sao Tome and Principe URY Uruguay URW Uruguay UZB Uzbekistan SRB Serbia VAT Vatican City Vanuatu SYC Seychelles VEN Venezuela VEN Vanuaru SYC Seychelles VEN Venezuela VEN Venezuela SEB Sierra Leone VNM Vietnam URW Vietnam STAM Sint Maarten VIR U.S. Virgin Islands URW Caledonia SYK Slovakia XWK Wake Island URW Caledonia SYK Slovakia XWK Wake Island URW Venezueland SYN Slovenia WLF Wallis and Futuna SIEB Soloman Islands XWB West Bank West Bank URW Caledonia SEB Soloman Islands XWB West Bank Sigera SOM Somalia ESH Western Sahara AN Nigeria ZAF South Africa YEM Yemen Zambia Sandwich Islands XSP Spatin Sundan SUR Suriname XSP Spatin Suriname XSP Spatiname XSP Spatiname XSP Suriname XSP Suriname XSP Sweden Suriname CHE Switzerland	SM	Federated States of Micronesia		Saint Lucia		
A Moldova SPM Saint Pierre and Miquelon ARE United Arab Emirate CO Monaco VCT Saint Vincent and the Grenadines GBR United Kingdom USA United States United Mongolia WSM Samoa USA United States United	MW					
Nonaco VCT Saint Vincent and the Grenadines GBR United Kingdom WSM Samoa USA United States WSM Samoa USA United States SMR San Marino AX1 Unknown RM Montserrat STP Sao Tome and Principe URY Uruguay Uruguay URW Uruguay URW Uruguay UZB Uzbekistan UZB VAT Vatican City Vanuatu UZB Uzbekistan UZB Uzbekistan UZB Sierra Leone VNM Vietnam UZB Ritish Virgin Islands UZB Uzbetan Uzberish UZB British Virgin Islands UZB Uzbetan Uzberish Uzbe	ИDA	-				United Arab Emirates
Mongolia WSM Samoa USA United States Montenegro SMR San Marino AX1 Unknown RR Montserrat STP Sao Tome and Principe URY Uruguay	1CO					United Kingdom
Montenegro SMR San Marino AX1 Unknown RR Montserrat STP Sao Tome and Principe URY Uruguay Montserrat STP Sao Tome and Principe URY Uruguay Montserrat SEN Senegal UZB Uzbekistan Montserrat SEN Senegal VUT Vanuatu Montserrat STP Sao Tome and Principe URY Uruguay Mozambique SEN Senegal VUT Vanuatu Mozambique SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VMM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna Migera SOM Somalia ESH Western Sahara Migeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South ZMB Zambia K Norfolk Island SSD South Sudan ZWE Zimbabwe Monthern Mariana Islands XSP Sprain Morthern Mariana Islands XSP Sprain Morthern Mariana Islands SDN Sudan SUR Suriname M Palau XSV Svalbard L Palmyra Atoll SWE Sweden CHE Switzerland	ИNG			Samoa		
R Montserrat STP Sao Tome and Principe URY Uruguay UZB Uzbekistan VAT Vatican City Venezuela VEN Venezuela VSM Vietnam URS U.S. Virigin Islands SVK Slovakia XWK Wake Islands XWK Wake Island SVK Slovakia XWK Wake Island ULS. Virigin Islands XWK Wake Island SVK Slovakia XWK Wake Island ULS. Virigin Islands XWK Wake Island SVK Slovakia XWK Wake Island SVK South Soloman Islands XWB West Bank West Bank West Bank West Bank ESH Western Sahara YEM Yemen ZMB Zambia	1NE	-		San Marino		
Mozambique SEN Senegal VUT Vanuatu M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen U Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe SD North Macedonia ESP Spain SD Northern Mariana Islands XSP Spratly Islands SD Norway LKA Sri Lanka SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden CHE Switzerland	ИSR	_				
M Namibia SRB Serbia VAT Vatican City U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe CD North Macedonia ESP Spain LP Northern Mariana Islands XSP Spratly Islands M Norway LKA Sri Lanka N Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	1AR	Morocco	SAU	Saudi Arabia	UZB	Uzbekistan
U Nauru SYC Seychelles VEN Venezuela V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands D New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna L Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara R Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South ZMB Zambia J Norfolk Island SSD South Sudan ZWE Zimbabwe J North Macedonia ESP Spain JR Norway LKA Sri Lanka JR Norway LKA Sri Lanka JR	1OZ	Mozambique	SEN	Senegal	VUT	Vanuatu
V Navassa Island SLE Sierra Leone VNM Vietnam L Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna L Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara R Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands ZMB Zambia K Norfolk Island SSD South Sudan ZWE Zimbabwe M North Macedonia ESP Spain MP Northern Mariana Islands XSP Spratly Islands MR Norway LKA Sri Lanka MR Norway LKA Sri Lanka MN <td>IAM</td> <td>Namibia</td> <td>SRB</td> <td>Serbia</td> <td>VAT</td> <td>Vatican City</td>	IAM	Namibia	SRB	Serbia	VAT	Vatican City
Nepal SGP Singapore VGB British Virgin Islands D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna C Nicaragua SLB Soloman Islands C Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe C North Macedonia ESP Spain C Norway LKA Sri Lanka C Norway LKA Sri Lanka C Norman SDN Sudan C Palau XSV Svalbard C Palmyra Atoll C New Caledonia SYM Singapore C Williams C SUR Suriname C Palamyra Atoll C New Panama CHE Switzerland	IRU	Nauru	SYC	Seychelles	VEN	Venezuela
D Netherlands SXM Sint Maarten VIR U.S. Virgin Islands L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna D Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen D Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain D Northern Mariana Islands XSP Spratly Islands D Norway LKA Sri Lanka D Noman SDN Sudan C Pakistan SUR Suriname D Palau XSV Svalbard D Nama C SWE Sweden D Nama C SWE Sweden D Nama C SWE Switzerland	(NV	Navassa Island	SLE	Sierra Leone	VNM	Vietnam
L New Caledonia SVK Slovakia XWK Wake Island L New Zealand SVN Slovenia WLF Wallis and Futuna C Nicaragua SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe CD North Macedonia ESP Spain AP Northern Mariana Islands XSP Spratly Islands AR Norway LKA Sri Lanka AN Oman SDN Sudan C Pakistan SUR Suriname AN Palau XSV Svalbard AN Panama CHE Switzerland	NPL	Nepal	SGP	Singapore	VGB	British Virgin Islands
L New Zealand SVN Slovenia WLF Wallis and Futuna SLB Soloman Islands XWB West Bank Western Sahara XAR Niger A Nigeria A Nigeria A Niue SGS South Africa YEM Yemen SGS South Georgia and South Sandwich Islands XMB West Bank Western Sahara YEM Yemen ZMB Zambia Zambia ZMB Zambia Zambia ZMB Zimbabwe ZmB Zimbabw	NLD	Netherlands	SXM	Sint Maarten	VIR	U.S. Virgin Islands
SLB Soloman Islands XWB West Bank R Niger SOM Somalia ESH Western Sahara A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	NCL	New Caledonia	SVK	Slovakia	XWK	Wake Island
R Niger SOM Somalia ESH Western Sahara ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan D North Macedonia ESP Spain IP Northern Mariana Islands R Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname M Palau XSV Svalbard D North Macedonia SWE Sweden C Panama CHE Switzerland	NZL	New Zealand	SVN	Slovenia	WLF	Wallis and Futuna
A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka NOMAN SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	NIC .	Nicaragua	SLB	Soloman Islands	XWB	West Bank
A Nigeria ZAF South Africa YEM Yemen J Niue SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe D North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands R Norway LKA Sri Lanka NOMAN SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	NER	Niger	SOM	Somalia	ESH	Western Sahara
SGS South Georgia and South Sandwich Islands K Norfolk Island SSD South Sudan ZWE Zimbabwe KD North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	IGA		ZAF	South Africa		Yemen
ID North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	IIU	_	SGS	-	ZMB	Zambia
ID North Macedonia ESP Spain IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	NFK	Norfolk Island	SSD	South Sudan	ZWE	Zimbabwe
IP Northern Mariana Islands XSP Spratly Islands IR Norway LKA Sri Lanka IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	1KD	North Macedonia				
LKA Sri Lanka SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	INP	Northern Mariana Islands		-		
IN Oman SDN Sudan K Pakistan SUR Suriname W Palau XSV Svalbard L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	IOR					
KPakistanSURSurinameWPalauXSVSvalbardLPalmyra AtollSWESwedenNPanamaCHESwitzerland	NMO	· · · · · · · · · · · · · · · · · · ·				
WPalauXSVSvalbardLPalmyra AtollSWESwedenNPanamaCHESwitzerland	'ΑΚ					
L Palmyra Atoll SWE Sweden N Panama CHE Switzerland	PLW					
N Panama CHE Switzerland	(PL					
	PAN					
	PNG	Papua New Guinea	SYR	Syria		
	(PR		2			

IATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

 $^{{\}rm *Codes\ were\ developed\ by\ the\ U.S.\ Government\ and\ endorsed\ by\ the\ Federal\ Geographic\ Data\ Committee.} \\ {\rm \underline{https://www.fgdc.gov/standards/news/GENC}}$

App	endix 2: NACC Occupa	tion C	odes				
Code	Occupation	Code	Occupation	Code	Occupation	Code	Occupation
100	Major professionals/ Higher Executives/ Proprietors of Large Concerns	200	Lesser Professionals/ Business Managers of Medium-sized Businesses	300	Administrative Personnel/Small Business Owners/ Minor Professionals	400	Clerical and Sales Workers/Technicians/ Owners of Little Businesses
101	Actuaries	201	Accountants	301	Actors	401	Bank tellers
102	Architects	202	Advertising executives	302	Administrative assistants	402	Bill collectors
103	Bank officers	203	Authors	303	Advertising agents	403	Bookkeepers
104	Certified public accountants	204	Branch managers	304	Artists	404	Claims examiners
105	Chief executives (CEO, CFO, COO)	205	Building contractors	305	Bakers	405	Drafters
106	Clergy (professionally trained)	206	Business managers	306	Beauty shop owners	406	Driving teachers
107	Commissioned officers in the military	207	Chiropractors	307	Chefs	407	Factory supervisors
108	Dentists	208	Computer programmer	308	Chief clerks	408	Small farm owners / farmers
109	Economists	209	Computer specialists	309	Clergy (not professionally trained)	409	Flower shop workers
110	Engineers (Masters level and above)	210	Database developer	310	Court reporters	410	Human resources workers
111	Financial managers	211	Editors	311	Credit managers	411	Laboratory technicians
112	Federal government officials	212	Engineers (no advanced degree)	312	Dental hygienists	412	Newsstand operators
113	Large business owners	213	Executive managers	313	Department store managers	413	Post office clerks
114	Lawyers / judges	214	Industrial farm owners	314	Deputy sheriffs	414	Railroad conductors
115	Mathematicians	215	Furniture business owners	315	Dietitians / Nutritionists	415	Railroad train engineers
116	Major contractors	216	Jewelers	316	Dispatchers	416	Receptionists
117	Orthodontists	217	Labor relations consultants	317	Florists	417	Route managers
118	Physicians	218	Librarians	318	Funeral directors	418	Sales clerks
119	Professor / University teachers	219	Manufacturing owners	319	Insurance agents	419	Secretaries / stenographer
120	Psychologists	220	Medium business owners	320	Laboratory assistants	420	Shipping clerks
121	Research scientists	221	Musicians / composers	321	Landscape planners	421	Tailors
122	Urban and regional planners	222	Nurses	322	Noncommissioned officers in the military (at or above rank of master sergeant / C.P.O.)	422	Tax clerks
123	Veterinarians	223	Office managers	323	Morticians	423	Telephone company workers
124	VP of large business	224	Opticians	324	Newspaper / TV reporters	424	Telephone operators
		225	Personnel managers	325	Photographers	425	Timekeepers
		226	Pharmacists	326	Piano teachers	426	Toll collectors
		227	Pilots	327	Radio / TV announcers	427	Tower operators
		228	Police chief / sheriff	328	Real estate agents	428	Truck dispatchers
		229 230	Postmaster Production managers (TV	329 330	Restaurant owners Sales representatives	429 430	Typists Utility workers
		231	/ radio) Public administration	331	Service managers	431	Warehouse clerks
		232	officials Public health officers	332	Small business owners	432	Window store trimmers
		233	Purchasing managers	333	Store managers	_	
		234	Real estate brokers	334	Surveyors		
		235	Research assistants	335	Title searchers		
		236	Sales engineers	336	Tool designers		
		237	Sales managers	337	Traffic managers		
		238	Social workers	338	Travel agents		
		239	State / Local government officials	339	Yard masters (railroad)		
		240	Teachers (Elementary & high school)				

Code	Occupation	Code	Occupation	Code	Occupation	Code	Occupation
500	Skilled Manual Employees	500	Skilled Manual Employees (cont.)	600	Machine Operators/ Semiskilled Employees	700	Unskilled Employees
501	Auto body repairers	538	Piano tuners	601	Apprentices (electrician / printers / etc.)	701	Amusement park workers
502	Barbers	539	Plumbers	602	Assembly line workers	702	Cafeteria workers
503	Boiler repairers	540	Police officers	603	Bartenders	703	Car cleaners
504	Bookbinders	541	Postal workers	604	Building superintendents	704	Child care workers (private household)
505	Brewers	542	Printers	605	Bus drivers	705	Construction laborers
506	Cabinet makers	543	Radio / TV maintenance	606	Cab / taxi drivers	706	Dairy workers
507	Carpenters	544	Railroad brake operators	607	Cashiers	707	Deck hands
508	Cement layers / finishers	545	Repair people	608	Child care workers (not private household)	708	Farm laborers
509	Checkers / examiners / inspectors	546	Seamstresses / seamsters	609	Cooks (short order)	709	Fishers
510	Cheese makers	547	Sheet metal workers	610	Corrections workers	710	Freight handlers
511	Construction forepeople	548	Ship smiths	611	Delivery people	711	Garbage collectors
512	Die makers	549	Shoe repairers	612	Dry cleaning pressers	712	Grave diggers
513	Electricians	550	Steelworkers	613	Elevator operators	713	Homemakers
514	Engravers	551	Tile layers	614	Enlisted military personnel (other than noncommissioned officers)	714	House cleaners
515	Exterminators	552	Tool makers	615	Factory machine operators	715	Janitors
516	Firefighters	553	Upholsterers	616	Factory workers	716	Junk / recycle sorters
517	Gardeners / landscapers	554	Utility line workers	617	Foundry workers	717	Laundry workers
518	Glassblowers	555	Weavers	618	Garage and gas station assistants	718	Messengers
519	Glaziers	556	Welders	619	Greenhouse workers	719	Peddlers
520	Gun smiths			620	Guards / security watch people	720	Porters
521	Hair stylists			621	Machine operators	721	Roofing laborers
522	Heavy equipment operators			622	Meat cutters / packers	722	Shoe shiners
523	Home repairs			623	Meter readers	723	Stagehands
524	Iron workers			624	Nursing aides / attendants	724	Stock handlers
525	Kitchen workers / cooks			625	Oil delivery people	725	Street cleaners
526	Locksmiths			626	Practical nurses	726	Unemployed
527	Machinists			627	Pump operators	727	Unskilled factory workers
528	Mail carriers			628	Receivers / checkers	728	Unspecified laborers
529	Maintenance forepeople			629	Servers (waiters / waitresses)	729	Window cleaners
530	Masons			630	Signal operators (railroad)	730	Woodchoppers
531	Mechanics			631	Truck drivers	731	Worked while incarcerated
532	Millwrights			632	Wood workers		2
533	Noncommissioned officers in the military (below rank of master sergeant / C.P.O.)			633	Wrappers (stores / factories)		
534	Painters						
535	Paperhangers						
536	Patrolmen						
537	Piano builders						



Form A1a: Social Determinants of Health

ADRC:	PTID:		Form date:	_//	Visit #:	Examiner's initials:				
Langu □1 Ei □2 S _l		Mode: ☐ 1 In-person ☐ 2 Remote (reason): ☐ 1 Telephone ☐ 2 Video ☐ 3 Mail ☐ 4 Electr ☐ 0 Not completed (reason): _	onic (e.g., email)			1=Too cognitively impaired 2=Too physically impaired 3=Homebound/nursing home 4=Refused in-person visit 5=Other 93=Concerns about reliability				
may feel ι	INSTRUCTIONS: The following questions are designed to gather information on your current and past life experience that we think may be important for brain health. There are no right or wrong answers, and you do not have to answer any question that makes you feel uncomfortable. If the question does not apply to your experience, feel free to check Prefer not to answer . You should fill out this form on your own, without help from your co-participant or study partner.									
Sect	tion 1 — Transportatio	n								
acco	is section we are trying to un mplishing important activition ications (these are only exam	es, such as going to the doc								
1.	Do you or someone in your h	iousehold currently own a c	ar?		0 No 1 Yes 8 Prefe	er not to answer				
2.	Do you have consistent acce	ss to transportation?			0 No 1 Yes 8 Prefe	er not to answer				
	et to the places they need to tions are trying to assess who				ar, or get	a ride. The next three				
3.	In the past 30 days, how ofte because of a problem with to		e the house wher	you wanted to	1 Often 2 Some 3 Neve	etimes				
4.	In the past 30 days, how ofte get somewhere because of a			ould be able to	1 Ofter 2 Some 3 Neve	etimes				
5.	In the past 30 days, how often has a lack of transportation kept you from medical appointments or from doing things needed for daily living? 1 Often 2 Sometimes 3 Never 8 Prefer not to answer									
Section 2 — Financial security										
	These next set of questions are designed to assess your current and past financial situation. If you do not feel comfortable with any question in this section, you can respond Prefer not to answer .									
6.	Which of these income grou Include income from all sour benefits, help from relatives, This information will be kept confi other person, organization or gov	ces such as wages, salaries, s rent from property, and so f idential and will not be shared in ernment entity.	social security or forth. a way that identifies	retirement	2 \$15,0 3 \$30, 4 \$75,0	\$14,999 000 – \$29,999 000 – \$74,999 000 and over er not to answer t know				
7.	How satisfied are you with yo	our current personal financia	al condition?		2 Satis 3 Some	pletely satisfied fied ewhat satisfied very satisfied at all satisfied er not to answer				

naccmail@uw.edu NATIONAL ALZHEIMER'S COORDINATING CENTER naccdata.org

Participant ID:	Form date:	/	/	Visit #:

Sec	tion 2 — Financial security	continued
8.	How difficult is it for you to meet monthly payments on your bills?	1 Not at all 2 Slightly 3 Moderately 4 Very 5 Extremely 8 Prefer not to answer
9.	months or longer, how upsetting has it been to you? 2 Yes, financial problems upsetting to me 3 Yes, financial problems somewhat upsetting t	for twelve months or longer for twelve months or longer, but not for twelve months or longer, and o me for twelve months or longer, and
10.	At any time, did you ever eat less than you felt you should because there wasn't enough money to buy food?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
11.	In the last 12 months, did you ever eat less than you felt you should because there wasn't enough money to buy food?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
12.	At any time, have you ended up taking less medication than was prescribed for you because of the cost?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
13.	<u>In the last 12 months</u> , have you ended up taking less medication than was prescribed for you because of the cost?	☐ 0 No ☐ 1 Yes ☐ 8 Prefer not to answer
14.	This is a picture of a ladder with 10 steps. Each step represents a level of status as far as money, education, and jobs. The highest step is step 10. This represents people with the most money, the most education, and the best jobs. Step 1 is the lowest step. This step represents people with the least money, least education, and the worst jobs or no job. Steps in between (2 through 9) represent those people who fall somewhere between those who are best off and those who are worst off. Where would you place yourself on this ladder compared to others in your community (or neighborhood)? The closer you are to step 10 the better off you think you are. Please mark the number where you would place yourself.	Best off → 10 3 4 Worst off
15.	What was your mother's (or primary person who raised you up until age 18) highest level of education completed at the time they were raising you? 1 Never attended school 2 Grades 1 through 8 (electric level of education completed at the time they were raising you? 3 Grades 9 through 11 (some 4 Grade 12 or GED (high 5 College 1 year to 3 year 6 College 4 years or more 8 Prefer not to answer/N 9 Do not know	ome high school) school graduate) rs (some college) e (college graduate)

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Sec	tion 3 — Social connections, activities, and environment					
	These next set of questions are designed to learn what you think about your social connections, the types of activities you spend your time on, and how you view your home and neighborhood.					
	wing are some statements to learn how you describe yourself in general. For each statemen ly represents your opinion.	t, select the number that most				
16.	I experience a general sense of emptiness	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer				
17.	I miss having people around	1 Strongly disagree 2 Disagree 3 Neither disagree or agree 4 Agree 5 Strongly agree 8 Prefer not to answer				
18.	I feel like I don't have enough friends	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer				
19.	I often feel abandoned	1 Strongly disagree 2 Disagree 3 Neither disagree or agree 4 Agree 5 Strongly agree 8 Prefer not to answer				
20.	I miss having a really close friend	☐ 1 Strongly disagree ☐ 2 Disagree ☐ 3 Neither disagree or agree ☐ 4 Agree ☐ 5 Strongly agree ☐ 8 Prefer not to answer				
The r	next four questions are about how you spend your time.					
21.	If your parents are still alive, how often do you have contact with them (including mother, father, mother-in-law, and father-in-law) either in person, by phone, mail, or email (e.g., any online interaction)?	0 Parents not living 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer				
22.	If you have children, how often do you have contact with your children (including child[ren]-in-law and stepchild[ren]) either in person, by phone, mail, or email (e.g., any online interaction)?	0 Do not have children 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer				

Participant ID: _____ Form date: ___ / ___ / ___ Visit #: ____

Soc	tion	3 — Social connections, activities, and envi	ironmont	continued	
23.	How	often do you have contact with close friends either in p I (e.g., any online interaction)?		0 Do not have close friends 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer	
24.	How often do you participate in activities outside the home (e.g., religious activities, educational activities, volunteer work, paid work, or activities with groups or organizations)? 0 Do not participate in activitie outside the home organizations)? 1 Once a year or less 2 Several times a year 3 Several times a month 4 Several times a week 5 Everyday or almost everyday 8 Prefer not to answer				
This	next s	et of questions is about how safe you feel in different co	ntexts.		
25.	How	safe do you feel in your home and community (or neigh	nborhood)?		
	25a.	Home		☐ 1 Very safe ☐ 2 Mostly safe ☐ 3 Unsafe at times ☐ 4 Very unsafe ☐ 8 Prefer not to answer	
	25b.	Community (or neighborhood)		☐ 1 Very safe ☐ 2 Mostly safe ☐ 3 Unsafe at times ☐ 4 Very unsafe ☐ 8 Prefer not to answer	
Sec	tion	4 — Experiences with the healthcare syster	n		
		five questions are about your experiences with the hea k about your regular medical doctors (not the doctors y			
26.		e past year, how often did you delay seeking medical ation for a problem that was bothering you?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of 5 Not applicable 8 Prefer not to answer	f the time	
27.		e past year, how often did you experience challenges ing a prescription?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of 5 Not applicable 8 Prefer not to answer	f the time	
28.		e past year, how often did you miss a follow-up ical appointment that was scheduled?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of 5 Not applicable 8 Prefer not to answer	f the time	

_____ Form date: ____ / ____ / ____ ___ Visit #:

Participant ID: ___

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Sec	tion 4 — Experiences with the healthcare syster	n continued
29.	In the past year, how often did you follow a doctor's advice or treatment plan when it was given?	1 All of the time 2 Most of the time 3 Sometimes 4 None or almost none of the time 5 Not applicable 8 Prefer not to answer
30.	Overall, which of these describes your health insurance, access to healthcare services, and access to medications?	1 Not available to any extent 2 Below the level of my needs 3 Able to meet my needs 4 Exceeds my needs 8 Prefer not to answer
Sec	tion 5 — Experiences of Discrimination	
	arch has shown that experiences of unfair treatment in daily li wing questions about whether you have experienced unfair tr	fe, for any reason, can negatively affect health. Please answer the reatment in the following ways.
31.	In your day-to-day life how often are you treated with less courtesy or respect than other people?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
32.	In your day-to-day life how often do you receive poorer service than other people at restaurants or stores?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
33.	In your day-to-day life how often do people act as if they think you are not smart?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
34.	In your day-to-day life how often do people act as if they are afraid of you?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer
35.	In your day-to-day life how often are you threatened or harassed?	1 Almost every day 2 At least once a week 3 A few times a month 4 A few times a year 5 Less than once a year 6 Never 8 Prefer not to answer

_____ Form date: ____ / ____ / ____ __ Visit #: ___

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Partio	cipant ID: Form date:	/ / Visit #:	
Sec	tion 5 — Experiences of Discrimination	continu	ed
36.	How frequently do you receive poorer service or treatment from doctors or in hospitals compared to other people?	☐ 1 All of the time ☐ 2 Most of the time ☐ 3 Sometimes ☐ 4 None or almost none of the time ☐ 5 Not applicable ☐ 8 Prefer not to answer	
37.	When reflecting on the day-to-day experiences in questions 31 to 36, what do you think are the main reasons for these experiences? (Check all that apply)	37a1.	

37a15. □ 1 Prefer not to answer

1 Very stressful
2 Moderately stressful
3 Not stressful

9 Don't know 8 Prefer not to answer

38. When you have had day-to-day experiences like those in

questions 31 to 36, would you say they have been very stressful, moderately stressful, or not stressful?



For	m A	A 2: Co-participant De	mographi	CS	For main and
ADRC:		PTID:	Fe	orm date://	Examiner's Visit #: initials:
	uage: inglish ipanish	Mode: □ 1 In-person □ 2 Remote (reason): □ 1 Telephone □ 2 Video □ 0 Not completed (reason):	Key (remote reas	on): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other	Key (not completed reason): 92=No co-participant 95=Physical problem 96=Cognitive/behavioral problem 97=Other 98=Verbal refusal
direc		IONS: This form is to be completed by the co-participant. For additional clariestion.			
Sec	tion	1 — Co-participant's Relatio	nship to Partic	ipant	
1.		: is the co-participant's relationship t cipant?	to the	Spouse, partner, or compariancé(e), boyfriend, girlfriend Child (by blood or through m Sibling (by blood or through 4 Other relative (by blood or t 5 Friend, neighbor, or some friends, work, or commun 6 Paid caregiver, health care	arriage or adoption) marriage or adoption) hrough marriage or adoption) one known through family, nity (e.g., church)
2.		long has the co-participant known t co-participant has known the participant			Years (999 = Unknown)
3.	Does	the co-participant live with the part	cicipant?	□o No	1 Yes (SKIP TO QUESTION 5)
4.		is the primary mode of contact with cipant?	n the	☐ 1 In-person ☐ 2 Telephone ☐ 3 Video conferencing	4 Texting or email 5 Social media platforms 6 Other (SPECIFY):
4		/hat is the approximate frequency o ontact?	f all types of	☐ 1 Daily ☐ 2 At least three times per week ☐ 3 Weekly	4 At least three times per month 5 Monthly 6 Less than once a month
4;	W	What is the average amount of time so with the participant during each encountered and average of all encountered and average of all encountered.	ounter?	1 Less than 5 minutes (appropriate for texting or email and may be applicable to other modes of contact as well)	2 5-15 minutes 3 15-30 minutes 4 30-60 minutes 5 Longer than one hour
5.	Is the	ere a question about the co-participa	ant's reliability?	□o No	1 Yes
Sec	tion 2	2 — Co-participant's Judgme	ent of Particip	ant's Memory	
Ask t	he nex	t three questions <u>directly to the co-p</u>	articipant.	,	
6.	Do yo wors	ou feel like the participant's memory e?	is becoming	0 No 1 Yes, but this does not wor 2 Yes, and this worries me 9 Unknown	ry me
7.		It how often does the participant ha mbering things?	ve trouble	1 Never 2 Rarely 3 Sometimes	☐ 4 Often ☐ 5 Very Often ☐ 9 Unknown
8.	parti	oared to 10 years ago, would you say cipant's memory is much worse, a lit e, a little better, or much better?		☐ 1 Much better ☐ 2 A little better ☐ 3 The same	4 A little worse 5 Much worse 9 Unknown

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org



Form A3: Participant Family History

ADRC:	PTID:	Form date://	Visit #: initials:	_
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired]	
□1 English	□ 1 In-person	2=Too physically impaired		
☐2 Spanish	☐ 2 Remote (reason):	3=Homebound or nursing home		
	☐ 1 Telephone ☐ 2 Video	4=Refused in-person visit		
		5=Other		

INSTRUCTIONS: This form is to be completed by a clinician with experience in evaluating participants with neurological and psychiatric diagnoses. Estimates are allowed if exact birth year or age at death is unknown. For additional clarification and examples, see the UDS Coding Guidebook for Form A3.

Section 1 - Biological parents

For any parent with a neurological or psychiatric diagnosis, the entire row must be filled out.

If the clinician cannot determine the primary neurological/psychiatric diagnosis after reviewing all available evidence, enter 99 = **Unknown** in the **Primary diagnosis** column, and *skip the subsequent questions in the row*. For a parent with no neurological or psychiatric diagnosis, enter **00** = **No known neurological/psychiatric diagnosis** in the **Primary diagnosis** column, and then *skip* the subsequent questions in the row. For a parent with a primary diagnosis but no secondary diagnosis, enter 88 = No secondary diagnosis in the Secondary diagnosis column.

	Birth year (9999=Unknown)	Age at death (888=N/A,	Primary dx*	Secondary dx*	Method of evaluation**	Age of onset of primary dx
		999 = Unknown)	SE	E LIST OF CODES	•••••	(999 = Unknown)
1a. Mother					_	
1b. Father					_	

Codes

*DIAGNOSES

- 00 No known neurological/psychiatric diagnosis
- 01 Alzheimer's Disease
- **02** Lewy Body dementia (includes DLB and PDD)
- 03 Vascular dementia
- 04 Stroke
- 05 FTLD* without motor neuron disease
- 06 FTLD* with motor neuron disease
- 07 Motor Neuron Disease
- 08 Parkinson's Disease
- 09 Prion pathology
- 10 Psychiatric condition
- 11 Dementia of unknown etiology
- 12 Other
- 88 No secondary diagnosis
- 99 Specific diagnosis unknown (acceptable if method of evaluation is not by exam or autopsy)

**METHOD OF EVALUATION

- 1 Participant/family report
- 2 Medical records
- (co-enrolled family members)
- 4 Autopsy (if autopsy report available)

*FTLD includes: bvFTD or FTD, PPA (any subtype), CBS or CBD, PSP

Abbreviations: bvFTD = behavioral variant frontotemporal dementia, CBS = corticobasal syndrome, CBD = corticobasal degeneration, DLB = dementia with Lewy bodies, FTD = frontotemporal dementia, PDD = Parkinson's disease with dementia, PPA = primary progressive aphasia, PSP = progressive supranuclear

ALZHEIMER'S COORDINATING naccmail@uw.edu naccdata.org

Participant ID:	Form date:	/	Visit #:
•			

YEAR OF BIRTH FOR FULL SIBLINGS & BIOLOGICAL CHILDREN: If birth year is unknown, please provide an approximate year on **UDS Initial Visit Form A3** and **UDS Follow-up Visit Form A3** so that the sibling or child with unknown birth year ends up in correct birth order relative to the other siblings/children.

Example: A participant is the oldest of three children. The participant was born in 1940 and the middle sibling in 1943; the youngest sibling's birth year is unknown. An approximate birth year of 1944 or later should be assigned to the youngest sibling.

Use that same birth year on **FTLD Module Form A3a**, *if applicable*, and across all UDS visits so that any new information on a particular sibling or child can be linked to previously submitted information. If it is impossible for the participant and co-participant to estimate the birth year, *enter* **9999=Unknown**.

Section 2 – Full siblings

2.	How many full siblings does the participant have?
	(77 = participant adopted or siblings unknown)
	If participant has no full siblings, SKIP TO QUESTION 3 ; otherwise, provide information on all full siblings.

For any full sibling with a neurological or psychiatric diagnosis, the entire row must be filled out.

If the clinician cannot determine the primary neurological/psychiatric diagnosis after reviewing all available evidence, enter **99** = **Unknown** in the **Primary diagnosis** column, and *skip the subsequent questions in the row*. For a full sibling with no neurological or psychiatric diagnosis, enter **00** = **No known neurological/psychiatric diagnosis** in the **Primary diagnosis** column, and then *skip the subsequent questions in the row*. For a full sibling with a primary diagnosis but no secondary diagnosis, enter **88** = **No secondary diagnosis** in the Secondary diagnosis column.

	Birth year (9999=Unknown)	Age at death (888=N/A,	Primary dx*	Secondary dx*	Method of evaluation**	Age of onset of primary dx
		999 = Unknown)	SE	E LIST OF CODES		(999 = Unknown)
2a. Sibling 1					_	
2b. Sibling 2					_	
2c. Sibling 3					_	
2d. Sibling 4					_	
2e. Sibling 5					_	
2f. Sibling 6					_	
2g. Sibling 7					_	
2h. Sibling 8					_	
2i. Sibling 9					_	
2j. Sibling 10					_	
2k. Sibling 11					_	
2l. Sibling 12					_	
2m. Sibling 13					_	
2n. Sibling 14					_	
20. Sibling 15					_	
2p. Sibling 16					_	
2q. Sibling 17					_	
2r. Sibling 18					_	
2s. Sibling 19					_	
2t. Sibling 20					_	

Participant ID:	Form date:	/	Visit #:

Section 3 - Biological children

3. How many biological children does the participant have?

If participant has no biological children, **END FORM HERE**; otherwise, provide information on all biological children.

For any biological child with a neurological or psychiatric diagnosis, the entire row <u>must be filled out</u>.

If the clinician cannot determine the primary neurological/psychiatric diagnosis after reviewing all available evidence, enter **99** = **Unknown** in the **Primary diagnosis** column, and *skip the subsequent questions in the row*. For a biological child with no neurological or psychiatric diagnosis, enter **00** = **No known neurological/psychiatric diagnosis** in the **Primary diagnosis** column, and then *skip the subsequent questions in the row*. For a biological child with a primary diagnosis but no secondary diagnosis, enter **88** = **No secondary diagnosis** in the Secondary diagnosis column.

	Birth year (9999=Unknown)	Age at death (888=N/A,	Primary dx*	Secondary dx*	Method of evaluation**	Age of onset of primary dx	
		999 = Unknown)	SE	E LIST OF CODES	•••••	(999 = Unknown)	
3a. Child 1					_		
3b. Child 2					_		
3c. Child 3					_		
3d. Child 4					_		
3e. Child 5					_		
3f. Child 6					_		
3g. Child 7					_		
3h. Child 8					_		
3i. Child 9					_		
3j. Child 10					_		
3k. Child 11					_		
3l. Child 12					_		
3m. Child 13					_		
3n. Child 14					_		
3o. Child 15					_		



Form A4: Participant Medications

ADRC:	PTID:	Form date://	Visit #: initials:	
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired		
□1 English	□ 1 In-person	2=Too physically impaired		
☐2 Spanish	☐ 2 Remote (reason):	3=Homebound or nursing home		
	□1 Telephone □2 Video	4=Refused in-person visit		
		5=Other		

INSTRUCTIONS: This form is to be completed by the clinician or ADRC staff. The purpose of this form is to record all prescription medications taken by the participant within the two weeks before the current visit. If the participant is receiving any treatments known to significantly impact Alzheimer's disease (AD) or Alzheimer's disease related dementias (ADRD) biomarkers as part of their clinical care at the time of clinical assessment (e.g., they are receiving lecanemab infusions), the treatment should be included on both this form and the A4a ADRD-Specific Treatments form.

For prescription medications not listed here, please follow the instructions at the end of this form. OTC (non-prescription) medications need not be reported; however, a short list of medications that could be either prescription or OTC follows the prescription list. For additional clarification and examples, see **UDS Coding Guidebook** for Form A4.

Is the participant currently taking any medications?

o No (END FORM HERE)

1 Yes

ME	DICATION NAME	RXNorm
	acetaminophen-HYDROcodone (Hycet,	214182
	Vicodin) albuterol (Proventil, ProAir HFA, RespiClick, Ventolin)	435
	alendronate (Binosto, Fosamax)	46041
	allopurinol (Aloprim, Duzallo, Zyloprim)	519
	alprazolam (Xanax)	596
	amlodipine (Norvasc)	17767
	apixaban (Eliquis)	1364430
	atenolol (Tenormin)	1202
	atorvastatin (Lipitor)	83367
	benazepril (Lotensin)	18867
	bupropion (Aplenzin, Budeprion, Wellbutrin, Zyban)	42347
	calcium acetate (Calphron, Eliphos, PhosLo Phoslyra)	214342
	carbidopa-levodopa (Duopa, Rytary, Sinemet)	103990
	carvedilol (Coreg)	20352
	celecoxib (Celebrex)	140587
	cetirizine (Aller-Tec, Zyrtec)	20610
	citalopram (Celexa)	2556
	clonazepam (Klonopin)	2598
	clopidogrel (Plavix)	32968
	cyanocobalamin (Nascobal, Vitamin B12)	11248
	diclofenac (Flector, Cambia, Zipsor)	3355
	diltiazem (Cardizem, Cardia XT, DILT-XR, Tiazac)	3443
	donepezil (Adlarity, Aricept)	135447
	duloxetine (Cymbalta, Irenka)	72625

ME	DICATION NAME	RXNorm
	enalapril (Vasotec)	3827
	ergocalciferol (Calcidol, Calciferol, Disdol, Vitamin D2)	4018
	escitalopram (Lexapro)	321988
	esomeprazole (Nexium)	283742
	estradiol (Estrace, Estrogel, Delestrogen, Yuvafem)	4083
	ezetimibe (Zetia)	341248
	ferrous sulfate (Feosol, Iron Supplement, Slow FE)	24947
	fexofenadine (Allegra, Wal-Flex)	87636
	finasteride (Propecia, Proscar)	25025
	fluoxetine (Prozac, Sarafem)	4493
	fluticasone (Flovent)	41126
	fluticasone nasal (Aller-Flo, Flonase)	1165656
	fluticasone-salmeterol (Advair, AirDuo)	284635
	furosemide (Lasix)	4603
	gabapentin (Gralise, Horizant, Neurontin)	25480
	galantamine (Razadyne, Reminyl)	4637
	glipizide (Glucotrol)	4821
	hydrochlorothiazide (Esidrix, Hydrodiuril, Microzide)	5487
	hydrochlorothiazide-triamterene (Dyazide, Maxzide)	548337
	latanoprost (Xalatan)	43611
	levothyroxine (Levoxyl, Synthroid, Tirosint)	10582
	lisinopril (Prinivil, Qbrelis, Zestril)	29046
	lorazepam (Ativan)	6470
	losartan (Cozaar)	52175
	lovastatin (Altocor, Altoprev, Mevacor)	6472

Part	icipant ID: Form dat	te:	/	/ Visit #:							
ME	DICATION NAME	RXNorm	ME	DICATION NAME	RXNorm						
	meloxicam (Mobic, Vivlodex)	41493		potassium chloride (K-Dur 10, K-Tab, Klor-con)	8591						
	memantine (Namenda)	6719		pravastatin (Pravachol)	42463						
	metformin (Glucophage, Glumetza, Riomet)	6809		quetiapine (Seroquel)	51272						
	metoprolol (Lopressor, Toprol-XL)	6918		ranitidine (Wal-Zan, Zantac)	9143						
	mirtazapine (Remeron)	15996		rivastigmine (Exelon)	183379						
	montelukast (Singulair)	88249		rosuvastatin (Crestor, Ezallor)	301542						
	naproxen (Aleve, Anaprox, Naprosyn)	7258		sertraline (Zoloft)	36437						
	niacin (Niacinol, Niacor, Niaspan, Nicotinic	7393		sildenafil (Viagra, Revatio)	136411						
	Acid)			simvastatin (FloLipid, Zocor)	36567						
Ш	nifedipine (Adalat, Afeditab CR, Procardia)	7417		tamsulosin (Flomax)	77492						
	nitroglycerin (Nitro-Bid, Nitro-Dur, Nitro-Time, Nitrostat, Rectiv)	4917		terazosin (Hytrin)	37798						
	omega-3 polyunsaturated fatty acids	4201		tramadol (ConZip, Ryzolt, Ultram)	10689						
	(Omacor, Lovaza, Vascazen)	4301		trazodone (Desyrel, Oleptro)	10737						
	omeprazole (Prilosec, Zegerid)	7646		valsartan (Diovan)	69749						
	oxybutynin (Ditropan, Oxytrol, Urotrol)	32675		venlafaxine (Effexor)	39786						
	pantoprazole (Protonix)	40790		warfarin (Coumadin, Jantoven)	11289						
	paroxetine (Paxil, Paxil CR, Pexeva)	32937		zolpidem (Ambien, Edluar, Intermezzo, Zolpimist)	39993						
	Commonly reported medications that may be purchased over the counter (but that may also be prescription):										
		that may also		escription):	- DVAI						
ME	DICATION NAME			escription): DICATION NAME	RXNorm						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol)	that may also		DICATION NAME docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease)	RXNorm 82003						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C)	RXNorm		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite)							
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin)	RXNorm 161		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride,	82003						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin	RXNorm 161 1151		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin)	82003 4511						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin)	RXNorm 161 1151 1191		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride,	82003 4511 4845						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H)	RXNorm 161 1151 1191 1588		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin)	82003 4511 4845 5640						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick,	RXNorm 161 1151 1191 1588 214342 1897		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist)	82003 4511 4845 5640 28889						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D)	RXNorm 161 1151 1191 1588 214342		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release)	82003 4511 4845 5640 28889 6711						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D)	RXNorm 161 1151 1191 1588 214342 1897 608343 1008264		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax)	82003 4511 4845 5640 28889 6711 221147						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D) cholecalciferol (Decara, Replesta, Vitamin D3)	RXNorm 161 1151 1191 1588 214342 1897 608343		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax) turmeric (Curcumin, Turmeric Root) ubidecarenone (Co Q-10) vitamin E (Alpha E, Aquasol-E, Aquavite-E,	82003 4511 4845 5640 28889 6711 221147 1114883 21406						
ME	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D)	RXNorm 161 1151 1191 1588 214342 1897 608343 1008264		docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax) turmeric (Curcumin, Turmeric Root) ubidecarenone (Co Q-10)	82003 4511 4845 5640 28889 6711 221147 1114883						
	acetaminophen (Actamin, Feverall, Ofirmev, Panadol, Tempra, Tylenol) ascorbic acid (Acerola C, C Complex, Vitamin C) aspirin (Ecotrin) biotin (Appearex, coenzyme R, Nail-ex, Vitamin H) calcium acetate (Calphorn, Domeboro) calcium carbonate (Caltrate, Rolaids, Tums) calcium carbonate/cholecalciferol (Cal-Quick, Caltrate-Plus D) calcium carbonate/ergocalciferol (O Cal-D) cholecalciferol (Decara, Replesta, Vitamin D3) chondroitin-glucosamine (Cidaflex, Osteo Bi-Flex)	RXNorm 161 1151 1191 1588 214342 1897 608343 1008264 2418 1008567 edication is	ME	docusate (Colace, Dioctyl SS, Ducsate Calcium, Dulcoease) folic acid (Folic Acid, Folvite) glucosamine (Glucosamine Hydrochloride, Optiflex-G, Synovacin) ibuprofen (Advil, Motrin, Nuprin) loratadine (Alavert, Allerclear, Claritin, Tavist) melatonin (Melatonin, Melatonin Time Release) polyethylene glycol 3350 (Clearlax, Miralax) turmeric (Curcumin, Turmeric Root) ubidecarenone (Co Q-10) vitamin E (Alpha E, Aquasol-E, Aquavite-E, Centrum Singles)	82003 4511 4845 5640 28889 6711 221147 1114883 21406 11256						

ADRC: ______ PTID: _____ Form date: ___/___/ ____ Visit #: ___



Examiner's

Form A4a: ADRD-Specific Treatments

Languag □1 Engl □2 Spai	lish	Mode: ☐ 1 In-perso ☐ 2 Remote ☐ 1 Te		Key (remote r	Key (remote reason): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other					
dement clinical those the of these treatme lifetime Informa pipelin	treatment expected to modify ADRD biomarkers?									
2.			nformation about the		it(s) and/or trial(s) als, use extended table on P	Paae 2):		nown (END FORM HERE)		
	ıry Dı	r ug Target hat apply)	Specific treatment and/ or trial	Start date (99/9999 =Unknown)	End date (month/year) (99/9999=Unknown; 88/8888=Ongoing)	How was treatmen	nt	If clinical trial, in which group was the participant?		
☐1 Tau ☐1 Inf ☐1 Syı	u lamm naptic europ	l beta nation c plasticity/ rotection urget(s)	NCT	/	/	1 Clinical ca 2 Clinical tr 3 Clinical ca and clinica	rial are	1 Active treatment 2 Placebo 9 Unknown		
1 Tau 1 Inf 1 Syr	i lamm naptic europ	l beta nation c plasticity/ rotection urget(s)		/	/	☐ 1 Clinical care ☐ 2 Clinical trial ☐ 3 Clinical care and clinical trial		1 Active treatment 2 Placebo 9 Unknown		
3.	(ARIA	A-E), amyloid	related imaging abn	ormalities-hemor	naging abnormalities–e rhage (ARIA-H), or othe modify ADRD biomarke	r major	□1 Yes	(END FORM HERE)		
	adverse events associated with treatments expected to modify ADRD biomarkers? What major adverse events associated with treatments expected to modify ADRD biomarkers did they experience? (check all that apply) 3a1. 1 Amyloid related imaging abnormalities—edema (ARIA-E) 3a2. 1 Amyloid related imaging abnormalities—hemorrhage (ARIA-H)									

Participant ID:	Form date:	/	/	Visit #:	

Please provide information about the clinical treatment(s) and/or trial(s) (continued from Page 1):									
Primary Drug Target (check all that apply)	Specific treatment and/ or trial	Start date (month/year) (99/9999 =Unknown)	End date (month/year) (99/9999=Unknown; 88/8888=Ongoing)	How was the treatment provided?	If clinical trial, in which group was the participant?				
☐ 1 Amyloid beta ☐ 1 Tau ☐ 1 Inflammation ☐ 1 Synaptic plasticity/ neuroprotection ☐ 1 Other target(s)		/	/	☐ 1 Clinical care ☐ 2 Clinical trial ☐ 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)	NCT	/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)	NCT	/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				
1 Amyloid beta 1 Tau 1 Inflammation 1 Synaptic plasticity/ neuroprotection 1 Other target(s)		/	/	1 Clinical care 2 Clinical trial 3 Clinical care and clinical trial	1 Active treatment 2 Placebo 9 Unknown				

IATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

¹ Cummings et al., "Alzheimer's disease drug development pipeline: 2024," Alzheimer's and Dementia. 2024 April 24; 10(2):e12465.



Form A5-D2: Participant Health History / Clinician-assessed Medical Conditions

ADRC:		PTID:	F	orm date:/	'/	Visit #:	Examiner's initials:
Language □1 Engli □2 Span	sh □1 In-personish □2 Remote		Key (remote reas	3=Homebou	tively impaired cally impaired ind or nursing home n-person visit		
and co- included	participant, as we	n is to be completed by Il as review of any med additional clarification wise stated.	ical records that ar	e available. An	y conditions iden	tified during the v	isit should be
Sectio	n 1 – Cigarett	e smoking, alcoh	ol, and substa	nce use			
Cigare	tte smoking						
1a.		nt smoked <u>more than</u> NO OR UNKNOWN,SKI			□o No	□1 Yes	☐9 UNK
1b.	Total years smok	ed (99 = Unknown)				_	
1c.	Average number	of packs smoked per o	2 1/2	cigarette to less pack to less that pack to less that	an 1 pack	☐ 4 1½ packs to☐ 5 2 packs or n☐ 9 Unknown	less than 2 packs nore
1d.	Has the participa	int smoked within <u>the</u>	last 30 days?		□o No	□1 Yes	☐9 UNK
1e.	-	quit smoking, specify I/ A, 999 = unknown)	the age at which t	hey last smoke	d — –		
Alcoho	ol use						
1f.	had a drink cont	onths, how often has the airling alcohol? KNOWN, SKIP TO QUES		0 Never 1 Monthly 2 2-4 times		3 2-3 times a value of 4 4 or more times of 9 Unknown	
1g.	beverages, how participant typic	he participant drinks a many standard drinks o ally consume? (Standa of wine, 1.50z of distilled	does the ord drink: 120z of	1 1 or 2 2 3 to 4 3 5 to 6		☐ 4 7 to 9 ☐ 5 10 or more ☐ 9 Unknown	
1h.		onths, how often did the drinks containing alco		0 Never 1 Less than 2 Monthly	once a month	3 Weekly 4 Daily or almo	ost daily
Substa	nce use						
1i.		nt used substances in llowing areas: work, di			al drugs that cau	used significant im	npairment in one
1	Ii1. Within the p	ast 12 months			□o No	☐1 Yes	□9 UNK
1	li2. Prior to 12 n	nonths ago			□o No	□1 Yes	□9 UNK
1j.		onths, how often has that the state of the s		0 Never 1 Monthly		3 2-3 times a s	

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

Participant ID:	Form date:	/	/	Visit #:	

In the following sections (pages 2-7) record the presence or absence of a <u>history of these conditions</u>, as determined by the clinician's best judgment following the medical history interview with the participant and co-participant, as well as review of any medical records that are available.

A COND	ITION SHOULD BE CONSID	ERED					
	Absent:	Recent/Active:	Remote	Inactive:	Unknown (UNK)		
It has n	It has never been present. It happened within the last year or still requires active management.		It existed or occurred in the past (more than one year ago) but was resolved or there is no treatment currently under way.		There is insufficient information available to assess this condition.		
Section	on 2 – Cardiovascu	lar disease					
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN	
2a.	Heart attack (heart arto (IF ABSENT OR UNKNO	ery blockage) — WN, SKIP TO QUESTION 2b)	О	□ 1	_2	<u></u> 9	
2	2a1. More than one he	art attack?		□o No	□1 Yes	☐9 UNK	
2	2a2. Age at most recen	t heart attack (999 = Unknown)					
2b.	Cardiac arrest (heart st	copped) — WN, SKIP TO QUESTION 2c)	О	□ 1	_2	<u> </u>	
2	2b1. Age at most recen	t cardiac arrest (999 = Unknown)					
2c.	Atrial fibrillation		По	<u></u> 1	2	<u></u> 9	
2d.	Coronary artery angio	plasty / endarterectomy /	О	□ ₁	□2	<u> </u>	
2e.	Coronary artery bypas (IF ABSENT OR UNKNO	s procedure — WN, SKIP TO QUESTION 2f)	□о	□ 1	2	<u> </u>	
2	2e1. Age at most recen	t surgery (999 = Unknown)					
2f.		ibrillator implantation — WN, SKIP TO QUESTION 2g)	О	□ ₁	□ ₂	<u> </u>	
;	2f1. Age at first implan	itation (999 = Unknown)					
2g.	Congestive heart failur	re (including pulmonary edema)	О	□ 1	\square_2	<u></u> 9	
2h.	Heart valve replaceme	ent or repair — WN, SKIP TO QUESTION 2i)	О	□ 1	□ ₂	<u> </u>	
2	2h1. Age at most recen	t procedure (999 = Unknown)					
2i.	Other cardiovascular o	lisease (specify):	О	□ 1	\square_2	<u></u> 9	
Section	on 3 – Cerebrovasc	ular disease					
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN	
3a.	· ·	exam (imaging is not required) — WN, SKIP TO QUESTION 3b)	О	□ 1	_2	9	
3	Ba1. More than one str	oke?		□o No	□1 Yes	□9 UNK	
3	Ba2. Age at most recen	t stroke (999 = Unknown)					
			NEVER IMPROVED	PARTIALLY IMPROVED	IMPROVED / BACK TO NORMAL	UNKNOWN	
3	3a3. What is the status	of stroke symptoms?	□ ₀	□ ₁	\square_2	<u></u> 9	

Section	on 3	– Cerebrovascular disease				continued
3	Ba4.	Carotid artery surgery or stenting? (IF NO OR UNKNOWN, SKIP TO QUESTION 3b)		□o No	□1 Yes	☐9 UNK
3	Ba5.	Age at most recent carotid artery surgery or stenting (999 = Unknown)				
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
3b.		nsient ischemic attack (TIA) — ABSENT OR UNKNOWN, SKIP TO QUESTION 4a)	□о		□2	<u></u> 9
3	b1.	Age at most recent TIA (999 = Unknown)				
Section	on 4	– Neurologic conditions				
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
4a.		kinson's disease (PD) — ABSENT OR UNKNOWN, SKIP TO QUESTION 4b)	О	□ 1		□ 9
4		Age at estimated PD symptom onset (999 = Unknow	n)			
4b.		ner parkinsonism disorder (e.g., DLB) — ABSENT OR UNKNOWN, SKIP TO QUESTION 4c)	□ ₀	□ 1		<u>9</u>
4	lb1.	Age at parkinsonism disorder diagnosis (999 = Unkn	own)			
4c.	feb (IF	lepsy and/or history of seizures (excluding childhood rile seizures) — REMOTE/INACTIVE, SKIP TO QUESTION 4c2, IF ABSENT UNKNOWN, SKIP TO QUESTION 4d)	□o		□ 2	<u></u> 9
4	4c1.	How many seizures has the participant had in the past 12 months?	□ 0 None □ 1 1 or 2 □ 2 3 or more □ 9 Unknown			
4	4c2.	Age at first seizure (excluding childhood febrile seizu (999 = Unknown)	ires)			
4d.	Chi	ronic headaches	\Box_0		\square_2	□ 9
4e.	Mu	ltiple sclerosis	\square_0		\square_2	□ 9
4f.	No	rmal-pressure hydrocephalus	О	□ 1	\square_2	□ 9
4g.	vio	petitive head impacts (e.g. from contact sports, intima lence, or military duty), regardless of whether it cause NO OR UNKNOWN, SKIP TO QUESTION 4h)	•	□o No	□1 Yes	□9 UNK
4g1. Indicate the source(s) of exposure for repeated hits to the head: (Check all that apply) 4g1a.						
4	lg2.	Indicate the total length of time in years that the par exposed to repeated hits to the head (e.g. playing American football for 7 years) (999 = Unit	·			

Form date: ____ / ___ / ___ __ Visit #:

Participant ID:

Sectio	n 4	– Neurologic conditions					continued	
4h.	play resi det	ad injury (e.g. in a vehicle accident, being hit by a ying sports or biking, in an assault, or during milit ulted in a period of feeling "dazed or confused, ails of the injury, or loss of consciousness (if mu sider most severe episode). (IF NO OR UNKNOWN	tary serv " being ultiple he	vice) that unable to recall ead injuries,	□o No	□1 Yes	□9 UNK	
41	h1.	After a head injury, what was the longest period of time that the participant was unconscious? □ 0 Less than 5 minutes □ 1 5 minutes to less than 30 minutes □ 2 30 minutes to less than 24 hours □ 3 1 day to less than 7 days □ 9 Unknown duration					, no loss of	
41	h2.	After a head injury, what was the longest period that the participant was "dazed or confused" or unable to recall details of the injury?	1 5 r 2 30	ss than 5 minutes minutes to less tha minutes to less th day to less than 7 c	n 30 minutes nan 24 hours	4 7 days or more 8 Not applicable and confused 9 Unknown dura	, never dazed	
41	h3.	Total number of head injuries in which the participant felt "dazed or confused", unable to recall details of the injury or experienced loss of consciousness?	0 No	2		☐ 3 6-12 ☐ 4 13 or more ☐ 9 Unknown		
41	h4.	Age of <u>first</u> head injury that resulted in a period of feeling "dazed or confused," being unable to recall details of the injury, or loss of consciousness: (999 = Unknown)						
41	h5.	Age of <u>most recent</u> head injury that resulted in a period of feeling "dazed or confused," being unable to recall details of the injury, or loss of consciousness: (999 = Unknown)						
Sectio	Section 5 – Medical conditions							
		conditions still require active management and	d/or me	dications, please	select " Recent	/ Active."		
				ADCENT	DECENT/ACTIV	REMOTE/	LINIKNIOWN	
5a.	Dia	betes —		ABSENT	RECENT/ACTIV		UNKNOWN	
		ABSENT OR UNKNOWN, SKIP TO QUESTION 5b)		□ o	□ 1	2	<u></u> 9	
5	a1.	Which type?			petes insipidus, l onal diabetes, p	atent autoimmune rediabetes)	diabetes/type	
5	a2.	Treated with (Check all that apply)	5a2a. 5a2b. 5a2c. 5a2d. 5a2e. 5a2f.	2a.				
5	a3.	Age at diabetes diagnosis (999 = Unknown)						
5b.		pertension (or taking medication for hypertension ABSENT OR UNKNOWN, SKIP TO QUESTION 5c)	on) —	□о	□ 1	\square_2	<u>9</u>	
51	b1.	Age at hypertension diagnosis (999 = Unknow	vn)					
5c.	cho	oercholesterolemia (or taking medication for hig lesterol) — ABSENT OR UNKNOWN, SKIP TO QUESTION 5d)	gh	□o	□ 1	□ 2	<u></u> 9	
5	c1.	Age at hypercholesterolemia diagnosis (999 =	= Unkno	wn)				
5d.	B12	deficiency		□ o	□ 1	\square_2	<u></u> 9	
5e.	Thy	roid disease		□ ₀	□ ₁	\square_2	<u></u> 9	

Participant ID:

Participant ID:	Form date:	/	/	Visit #:	

Section	on 5	- Medical conditions						continued
				ABS	ENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
5f.		hritis — <mark>ABSENT OR UNKNOWN, SKIP TO QUESTION 5g</mark>)	1] ₀	□1	\square_2	<u></u> 9
	5f1.	Type of arthritis (Check all that apply)	5f1a. 5f1b. 5f1c. 5f1d.	1 Os	neumatoi steoarthr ther (SPE nknown	itis		
	5f2.	Regions affected (Check all that apply)	5f2a. 5f2b. 5f2c. 5f2d.	1 Lo	oper extro ower extro oine oknown			
5g.	Inc	ontinence — urinary (occurring at least weekly	<i>'</i>)]0	□ 1	\square_2	<u></u> 9
5h.	Inc	ontinence — bowel (occurring at least weekly)] ₀	□ 1	\square_2	<u></u> 9
5i.		ep apnea — (IF ABSENT, REMOTE/INACTIVE, O KNOWN, SKIP TO QUESTION 5j)	R]0	□ 1	2	<u></u> 9
	5i1.	Typical use of breathing machine (e.g. CPAP) night over the past 12 months	at	<u>2</u> > -	one 4 hours p 4 hours p nknown			
	5i2.	Typical use of an oral device or implanted breathing pacemaker for sleep apnea at nighthe past 12 months?	ht over	2 >	one 4 hours p 4 hours p nknown			
5j.	REI	M sleep behavior disorder (RBD)]0	□ 1	\square_2	<u></u> 9
5k.		posomnia/Insomnia (occurring at least weekly o uiring medication)	or]0	□ 1	\square_2	<u></u> 9
5l.	Otł	ner sleep disorder (specify):]0		\square_2	<u></u> 9
5m.	(Re	ncer, primary or metastatic — port all known diagnoses. Exclude non-melanor ncer. IF ABSENT OR UNKNOWN, SKIP TO QUESTI]0	□ 1	□ 2	<u></u> 9
5	m1.	Type of cancer (Check all that apply)	5m1a. 5m1b. 5m1c.	□1 M 5r 5r	etastatic n1b1	on-metastatic (CHECK ALL THA 1 Metastatic to 1 Metastatic to		rain
5	m2.	Primary site of cancer: (Check all that apply)	5m2a. 5m2b. 5m2c. 5m2d. 5m2e. 5m2f.		east olon	:CIFY):		
5	m3.	Type of cancer treatment (Check all that apply)	5m3a. 5m3b. 5m3c. 5m3d. 5m3e. 5m3f. 5m3g.	1 Su 1 Im 1 Bo 1 Ch	adiation orgical Re nmunoth one marro nemother ormone t ther (SPE	erapy ow transplant rapy herapy		
5	m4.	Age at most recent cancer diagnosis (999 = 1	Unknown)				

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Participa	ant ID): Form date:	/ /	v	isit #:	
Section	on 5	– Medical conditions				continued
			ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
5n.		VID-19 infection — ABSENT OR UNKNOWN, SKIP TO QUESTION 50)	□о	□ ₁	\square_2	<u></u> 9
5	in1.	Requiring hospitalization?		□o No	□1 Yes	☐9 UNK
5o.	Ast	hma/COPD/pulmonary disease	\square_0		\square_2	<u></u> 9
5p.		ronic kidney disease — ABSENT OR UNKNOWN, SKIP TO QUESTION 5q)	□ ₀	□ 1	\square_2	<u> </u>
5	р1.	Age at diagnosis (999 = Unknown)				
5q.		er disease — ABSENT OR UNKNOWN, SKIP TO QUESTION 5r)	О	□ 1	□ 2	<u></u> 9
5	iq1.	Age at diagnosis (999 = Unknown)				
5r.		ipheral vascular disease — ABSENT OR UNKNOWN, SKIP TO QUESTION 5s)	□ ₀	□ 1	\square_2	9
	5r1.	Age at diagnosis (999 = Unknown)				
5s.		man Immunodeficiency Virus (HIV) — ABSENT OR UNKNOWN, SKIP TO QUESTION 5t)	□ ₀	□ 1	\square_2	<u> </u>
	5s1.	Age at diagnosis (999 = Unknown)				
5t.		ner medical conditions or procedures ECIFY):	О	□ 1	\square_2	<u></u> 9
Section	on 6	- Psychiatric conditions				
		liagnose a disorder, DSM-5-TR criteria require that sy				
occupa	tiona	al, or other important areas of functioning. For more gu	uidance see the U	JDS Coding Guide	ebook, Form A5/ REMOTE/	D2.
			ABSENT	RECENT/ACTIVE	INACTIVE	UNKNOWN
6a.	De	pressive disorder				
6	5a1.	Major depressive disorder (DSM-5-TR criteria*)	□o	1	_2	<u></u> 9
6	5a2.	Other specified depressive disorder (DSM-5-TR criteria*)	□о	□1	□ ₂	<u></u> 9
6	5a3.	If Recent/Active depressive disorder (Q6a1 or Q6a2), choose if treated or untreated.	0 Untreated 1 Treated wi	th medication and	d/or counseling	
6b.	Bip	olar disorder (DSM-5-TR criteria*)	□0	□ ₁	2	<u></u> 9
6с.		nizophrenia or other psychosis disorder (DSM-5-TR eria*)	□о	□ 1	\square_2	<u> </u>
6d.		kiety disorder (DSM-5-TR criteria*) ABSENT OR UNKNOWN, SKIP TO QUESTION 6e)	□0	□ 1	\square_2	<u> </u>
6	id1.	Generalized Anxiety Disorder	□ ₀	□ ₁	\square_2	<u></u> 9
6	id2.	Panic Disorder	□ ₀	□ ₁	\square_2	<u></u> 9
6	id3.	Obsessive-compulsive disorder (OCD)	□ ₀	□ ₁	\square_2	<u></u> 9
6	id4.	Other (SPECIFY):	О	□ 1	\square_2	□ 9
6e.		st-traumatic stress disorder (PTSD) (DSM-5-TR eria*)	О	□ 1	2	<u></u> 9

Participa	int ID	:	Form date: _	/	/	Vi	sit #:	
Section	n 6	- Psychiatric condition	ons					continued
					ABSENT	RECENT/ACTIVE	REMOTE/ INACTIVE	UNKNOWN
6f.	spe	velopmental neuropsychiat ctrum disorder [ASD], attenti order [ADHD], dyslexia)	_		□o		□ 2	<u></u> 9
6g.		ner psychiatric disorders ECIFY):			О	□ 1	\square_2	<u></u> 9
Section	n 7	– Menstrual and rep	roductive heal	lth				
If questi	ons c	about menstrual and reprodu	uctive health are rel	levant to tl	his participant, c	ontinue to questior	7a. Otherwise, E	ND FORM HERE.
7a.	(88	w old was the participant w 8 = Never had a menstrual pe NEVER HAD A MENSTRUAL F	eriod, 999 = Unknow	vn)	strual period?			
7b.	(88	w old was the participant w 8 = Still menstruating, 999 = STILL MENSTRUATING, SKIP	Unknown)	r last men	strual period?			
7с.	 If the participant has stopped having menstrual periods, please indicate the reason. (Check all that apply) 7c1.						HRT)	
7d.	(e.g	s the participant taken fema g. estrogen)? NO OR UNKNOWN, SKIP TO (cement pi	lls or patches	□o No	□1 Yes	□9 UNK
7	d1.	How many years in total?	(999 = Unknown)					
7	d2.	Age at first use	(999 = Unknown)					
7	d3.	Age at last use	(888= Still present	tly using, 9	999 = Unknown)			
7e.		s the participant ever taken NO OR UNKNOWN, END FOR	· · · · · · · · · · · · · · · · · · ·	?		□o No	□1 Yes	□9 UNK
7	'e1.	How many years in total?	(999 = Unknown)					
7	'e2.	Age at first use	(999 = Unknown)					
7	'e3.	Age at last use	(888= Still present	tly using, 9	999 = Unknown)			




Form B1: EVALUATION FORM - Vital Signs and Anthropometrics

ADRC:	PTID:	Form date:	/ Visit #:	initials:
Language:	Mode:	Key (not completed reason):	94=Remote visit	
☐1 English	□ 1 In-person		95=Physical problem	
☐2 Spanish	□ o Not completed (reason):		96=Cognitive/behavioral problem	
			97=Other	
			98=Verbal refusal	

INSTRUCTIONS: This form is to be completed by the clinician or appropriately trained research personnel. For additional clarification and examples, see the **UDS Coding Guidebook** for Form B1.

Section 1 - Participant vital signs and anthropometrics **1.** Participant height (inches) $(88.8 = not \ assessed)$ 2. Participant weight (lbs.) (888 = not assessed)

Instructions for measuring waist and hip circumference in adults



Waist circumference should be measured at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest, using a stretch resistant tape. Hip circumference should be measured around the widest portion of the buttocks, with the tape parallel to the floor.

For both measurements: Participant should stand with feet close together, arms at the side and body weight evenly distributed, and should wear little clothing. The participant should be relaxed, and the measurements should be taken at the end of a normal expiration. Each measurement should be taken twice and entered here. If the difference between the two measurements exceeds 0.5 inches, the two measurements should be repeated.

Source: Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8-11 December 2008.

Source: NHLBI Obesity Education Initiative, nhlbi.nih.gov

3.	Ent	er two waist circumference measurements (inches):	
	•	Measurement 1		(888 = not assessed)
	•	Measurement 2		(888 = not assessed)
4.	Ent	er two hip circumference measurements (in	ches):	
	•	Measurement 1		(888 = not assessed)
	•	Measurement 2		(888 = not assessed)

ALZHEIMER'S COORDINATING CENTER naccdata.org

Sec	tior	n 1 – Participant vital sig	gns and anthro	opometrics		continued
5.		er two readings spaced at least detailed instructions below.	t one minute apar	t for each arm.		
	5a.	Participant blood pressure - L	eft arm:			
	٠	Reading 1		_/	(888/888= not assessed)	
	•	Reading 2		_/	(888/888= not assessed)	
	5b.	Participant blood pressure - F	Right arm:			
	•	Reading 1		_/	(888/888= not assessed)	
	•	Reading 2		_/	(888/888= not assessed)	
6.	Par	ticipant resting heart rate (puls	se)		(888 = not assessed)	

Visit #:

Steps for proper blood pressure measurement

STEP 1 - Properly prepare the participant:

Participant ID:

- Have the participant relax, sitting in a chair (feet on floor, back supported) for >5 minutes
- · The participant should avoid caffeine, exercise, and smoking for at least 30 minutes before measurement.

Form date:

- Ensure that participant has emptied his/her bladder.
- · Neither the participant nor the observer should talk during the rest period or during the measurement.
- Remove all clothing covering the location of cuff placement.
- · Measurements made while the participant is sitting or lying on an examining table do not fulfill these criteria.

STEP 2 - Use proper technique for BP measurements

- Use a BP measurement device that has been validated and ensure that the device is calibrated periodically.
- Support the participant's arm (e.g., have it resting on a desk).
- Position the middle of the cuff on the participant's upper arm at the level of the right atrium (midpoint of the sternum).
- Use the correct cuff size, such that the bladder encircles 80% of the arm, and note if a larger- or smaller-than-normal cuff size is used.
- Either the stethoscope diaphragm or bell may be used for auscultatory readings.

STEP 3 - Take proper measurements

- Take two BP readings in both arms.
- Separate the second set of measurements from the first by one minute.
- For auscultatory determinations, use a palpated estimate of radial pulse obliteration pressure to estimate SBP. Inflate the cuff 20-30 mm Hg above this level for an auscultatory determination of the BP level.
- For auscultatory readings, deflate the cuff pressure 2 mm Hg per second, and listen for Korotkoff sounds.

STEP 4 - Properly document accurate BP readings

- Record SBP and DBP. If using the auscultatory technique, record SBP and DBP as onset of the first Korotkoff sound and disappearance of all Korotkoff sounds, respectively, using the nearest even number.
- · Record the two readings of SBP and DBP in the left arm, and the two readings of SBP and DBP in the right arm.

STEP 5 - Give BP readings and interpretation to the participants

It is recommended to provide participants with the SBP/DBP readings both orally, and in writing.

Source: Checklist for accurate measurement of BP adapted from AHA Guidelines, Whelton PK et al., Hypertension. 2018; 71: e13-e11.

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

UDSv4.0, Initial Visit Packet, Form B1: EVALUATION FORM—Vital Signs and Anthropometrics, January 2025

Page 2 of 2



Form B3: Unified Parkinson's Disease Rating Scale (UPDRS¹) - Motor Exam

ADRC:	PTID:	Form date: _	//	Visit #:	Examiner's initials:
Language: 1 English 2 Spanish INSTRUCTION administered contributions track the degradditional cla	Mode: □ 1 In-person □ 0 Not completed (reason): NS: This form is to be completed by to all participants. Clinician should or explanations for the findings. There of parkinsonism over time. The Unification and scoring instructions, ecorded examples of administrative Neurosci. 2009 Oct; Chapter 10:	the clinician or other trained record results as observed re is form is intended to 1) dete JPDRS is not intended to estable eee UDS Coding Guideboots is on, see Perlmutter JS. A	94=Remote visit 95=Physical problem 96=Cognitive/behavion 97=Other 98=Verbal refusal I health professional agardless of whether armine the degree of publish the presence of the for Form B3. Checuses the process of the presence of the pres	The motor exame there are non-paparkinsonism on a disence of park ck only one box p	n should be Irkinsonian any visit, and 2) insonism. For er question.
	ional) If the clinician completes to		d determines all ite	ems are normal,	check this box. If
1. Speech	2 Monotone, slurre	oression, diction and/or volued but understandable; modent, difficult to understand.			
2. Facial exp	1 Minimal hypomi 2 Slight but definit 3 Moderate hypon	mia, could be normal "poker cely abnormal diminution of nimia; lips parted some of th facies with severe or comple CIFY):	facial expression ne time nte loss of facial expr	ression; lips parte	d ¼ inches or more
3. Tremor a	at rest				
3a. Face, lips	1 Slight and infreq 2 Mild in amplitud 3 Moderate in amp	e and persistent; or modera plitude and present most of tude and present most of th	the time	only intermitten	tly present
3b. Right ha	1 Slight and infreq 2 Mild in amplitud 3 Moderate in ampli 4 Marked in ampli	uently present e and persistent; or modera olitude and present most of tude and present most of th	the time	only intermitten	tly present
3c. Left hand	1 Slight and infreq 2 Mild in amplitud 3 Moderate in ampli 4 Marked in ampli	uently present e and persistent; or modera blitude and present most of tude and present most of th CIFY):	the time	only intermitten	tly present

1-Fahn S, Elton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, Vol. 2. Florham Park, NJ: Macmillan Healthcare Information, 1987:153–163, 293–304. Reproduced by permission of the author.

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

3. Tremor at rest	continued
3d. Right foot	□ 0 Absent □ 1 Slight and infrequently present □ 2 Mild in amplitude and persistent; or moderate in amplitude, but only intermittently present □ 3 Moderate in amplitude and present most of the time □ 4 Marked in amplitude and present most of the time □ 8 Untestable (SPECIFY):
3e. Left foot	 Absent Slight and infrequently present Mild in amplitude and persistent; or moderate in amplitude, but only intermittently present Moderate in amplitude and present most of the time Marked in amplitude and present most of the time Untestable (SPECIFY):
4. Action or postur	ral tremor of hands
4a. Right hand	□ 0 Absent □ 1 Slight; present with action □ 2 Moderate in amplitude, present with action □ 3 Moderate in amplitude with posture holding as well as action □ 4 Marked in amplitude; interferes with feeding □ 8 Untestable (SPECIFY):
4b. Left hand	 Absent Slight; present with action Moderate in amplitude, present with action Moderate in amplitude with posture holding as well as action Marked in amplitude; interferes with feeding Untestable (SPECIFY):
5. Rigidity (judged on passive move	ement of major joints with participant relaxed in sitting position; cogwheeling to be ignored)
5a. Neck	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):
5b. Right upper extremity	 Absent Slight or detectable only when activated by mirror or other movements Mild to moderate Marked, but full range of motion easily achieved Severe; range of motion achieved with difficulty Untestable (SPECIFY):
5c. Left upper extremity	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):
5d. Right lower extremity	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):

Form date: ____ / ___ / ___ __ Visit #:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Participant ID:

5. Rigidity	
(judged on passive mo	ovement of major joints with participant relaxed in sitting position; cogwheeling to be ignored) continued
5e. Left lower extremity	□ 0 Absent □ 1 Slight or detectable only when activated by mirror or other movements □ 2 Mild to moderate □ 3 Marked, but full range of motion easily achieved □ 4 Severe; range of motion achieved with difficulty □ 8 Untestable (SPECIFY):
6. Finger taps (participant taps thur	mb with index finger in rapid succession)
6a. Right hand	 Normal Mild slowing and/or reduction in amplitude Moderately impaired; definite and early fatiguing; may have occasional arrests in movement Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement Can barely perform the task. Untestable (SPECIFY):
6b. Left hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
7. Hand moveme	
(participant opens an	nd closes hands in rapid succession)
7a. Right hand	 Normal 1 Mild slowing and/or reduction in amplitude 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement 4 Can barely perform the task. 8 Untestable (SPECIFY):
7b. Left hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
The second se	ing movements of hands movements of hands, vertically and horizontally, with as large an amplitude as possible, both hands simultaneously)
8a. Right hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
8b. Left hand	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
8a. Right hand	o Normal 1 Mild slowing and/or reduction in amplitude 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement 4 Can barely perform the task. 8 Untestable (SPECIFY): 0 Normal 1 Mild slowing and/or reduction in amplitude 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement 4 Can barely perform the task.

Form date: ____ / ___ / ___ __ Visit #:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

9. Leg agility (participant taps heel on	the ground in rapid succession, picking up entire leg; amplitude should be at least 3 inches)
9a. Right leg	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
9b. Left leg	□ 0 Normal □ 1 Mild slowing and/or reduction in amplitude □ 2 Moderately impaired; definite and early fatiguing; may have occasional arrests in movement □ 3 Severely impaired; frequent hesitation in initiating movements or arrests in ongoing movement □ 4 Can barely perform the task. □ 8 Untestable (SPECIFY):
10. Arising from chair (participant attempts to rise from a straight-backed chair, with arms folded across chest)	□ 0 Normal □ 1 Slow; or may need more than one attempt □ 2 Pushes self up from arms of seat. □ 3 Tends to fall back and may have to try more than one time, but can get up without help □ 4 Unable to arise without help □ 8 Untestable (SPECIFY):
11. Posture	□ 0 Normal □ 1 Not quite erect, slightly stooped posture; could be normal for older person □ 2 Moderately stooped posture, definitely abnormal; can be slightly leaning to one side □ 3 Severely stooped posture with kyphosis; can be moderately leaning to one side □ 4 Marked flexion with extreme abnormality of posture □ 8 Untestable (SPECIFY):
12. Gait	□ 0 Normal □ 1 Walks slowly; may shuffle with short steps, but no festination (hastening steps) or propulsion □ 2 Walks with difficulty, but requires little or no assistance; may have some festination, short steps, or propulsion □ 3 Severe disturbance of gait requiring assistance □ 4 Cannot walk at all, even with assistance □ 8 Untestable (SPECIFY):
13. Posture stability (response to sudden, strong posterior displacement produced by pull on shoulders while participant erect with eyes open and feet slightly apart; participant is prepared)	□ 0 Normal erect □ 1 Retropulsion, but recovers unaided □ 2 Absence of postural response; would fall if not caught by examiner □ 3 Very unstable, tends to lose balance spontaneously □ 4 Unable to stand without assistance □ 8 Untestable (SPECIFY):
14. Body bradykinesia and hypokinesia (combining slowness, hesitancy, decreased arm swing, small amplitude, and poverty of movement in general)	□ 0 None □ 1 Minimal slowness, giving movement a deliberate character; could be normal for some persons; possibly reduced amplitude □ 2 Mild degree of slowness and poverty of movement which is definitely abnormal; alternatively, some reduced amplitude □ 3 Moderate slowness, poverty or small amplitude of movement □ 4 Marked slowness, poverty or small amplitude of movement □ 8 Untestable (SPECIFY):
15. Total UPDRS Score (If one or more items are chec "8=Untestable", enter 888)	cked (0-108, 888)

Form date: ____ / ____ / ____ Visit #:



Form B4: CDR® Dementia Staging Instrument

PLUS NACC FTLD Behavior & Language Domains (CDR® Plus NACC FTLD)

ADRC:	PTID:	Form date://		initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired]	
☐1 English	□ 1 In-person	2=Too physically impaired		
☐2 Spanish	☐ 2 Remote (reason):	3=Homebound or nursing home		
	□1 Telephone □2 Video	4=Refused in-person visit		
		5=Other		
			1	

INSTRUCTIONS: This form is to be completed by the clinician or other trained health professional, based on co-participant report and behavioral and neurological exam of the participant. In the extremely rare instances when no co-participant is available, the clinician or other trained health professional must complete this form using all other available information and his/her best clinical judgment. Score only as decline from previous level due to cognitive loss, not impairment due to other factors, such as physical disability. For information on the required online CDR training, see the **UDS Coding Guidebook** for **Form B4.**

Section 1 - CDR® Dementia Staging Instrument¹

Impairment					
Please enter scores (below):	None = 0	Questionable = 0.5	Mild = 1	Moderate = 2	Severe = 3
1. Memory	No memory loss, or slight inconsistent forgetfulness	Consistent slight forgetfulness; partial recollection of events; "benign" forgetfulness	Moderate memory loss, more marked for recent events; defect interferes with everyday activities	Severe memory loss; only highly learned material retained; new material rapidly lost	Severe memory loss; only fragments remain
2. Orientation	Fully oriented	Fully oriented with time relationships; oriented for place at examination; may have geographic disorientation elsewhere Moderate difficulty with time relationships; oriented for place at examination; may have geographic disorientation elsewhere		Oriented to person only	
3. Judgment & Problem Solving	Solves everyday problems, handles business and financial affairs well; judgment good in relation to past performance	Slight impairment in solving problems, similarities, and differences	Moderate difficulty in handling problems, similarities, and differences; social judgment usually maintained	Severely impaired in handling problems, similarities, and differences; social judgment usually impaired	Unable to make judgments or solve problems
4. Community Affairs	Independent function at usual level in job, shopping, volunteer and social groups	Slight impairment in these activities	Unable to function independently at these activities, although may still be engaged in some; appears normal to casual inspection	No pretense of independent function outside the home; appears well enough to be taken to functions outside the family home	No pretense of independent function outside the home; appears too ill to be taken to functions outside the family home
5. Home & Hobbies	Life at home, hobbies, and intellectual interests well maintained	Life at home, hobbies, and intellectual interests slightly impaired	Mild but definite impairment of function at home; more difficult chores abandoned; more complicated hobbies and interests abandoned	Only simple chores preserved; very restricted interests, poorly maintained	No significant function in the home
6. Personal Care • <u>0</u>	Fully capable of self-care (= 0)		Needs prompting	Requires assistance in dressing, hygiene, keeping of personal effects	Requires much help with personal care; frequent incontinence
7. CDR Sum o	of Boxes	·	8. Global CDR	·	

'Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43(11):2412-4, 1993. Copyright@ Lippincott, Williams & Wilkins. Reproduced by permission.

ALZHEIMER'S COORDINATING naccmail@uw.edu naccdata.org

Participant ID:	Form date: /	/	Visit #:

Section 2 - NACC FTLD Behavior & Language Domains

Impairment					
Please enter scores (below):	None = 0	Questionable = 0.5	Mild = 1	Moderate = 2	Severe = 3
9. Behavior, Comportment, & Personality ²	Socially appropriate behavior	Questionable changes in comportment, empathy, appropriateness of actions	Mild but definite changes in behavior	Moderate behavioral changes, affecting interpersonal relationships and interactions in a significant manner	Severe behavioral changes, making interpersonal interactions all unidirectional
10. Language ³	No language difficulty, or occasional mild tip- of-the-tongue	Consistent mild word- finding difficulties; simplification of word choice; circumlocution; decreased phrase length; and/or mild comprehension difficulties	Moderate word-finding difficulty in speech; cannot name objects in environment; reduced phrase length and/or agrammatical speech and/or reduced comprehension in conversation and reading	Moderate to severe impairments in either speech or comprehension; has difficulty communicating thoughts; writing may be slightly more effective	Severe comprehension deficits; no intelligible speech

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

²Excerpted from the Frontotemporal Dementia Multicenter Instrument & MR Study (Mayo Clinic, UCSF, UCLA, UW).
³Excerpted from the PPA-CDR: A modification of the CDR for assessing dementia severity in patients with primary progressive aphasia (Johnson N, Weintraub S, Mesulam MM),



Form B5: BEHAVIORAL ASSESSMENT – Neuropsychiatric Inventory Questionnaire (NPI-Q1)

ADRC: _	PTID: Form date: _	/_	/_		Vis	it #:		initial	:	
Langua □1 En □2 Sp	glish \square 1 In-person \square 2=Too \square anish \square 2 Remote (reason): \square 3=Hom \square 1 Telephone \square 2 Video \square 4=Refu	Key (remote reason): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other Key (not completed reason): 95=Physical problem 96=Cognitive/behavioral prob 97=Other 98=Verbal refusal							em	
descri	INSTRUCTIONS : This form is to be completed by the clinician or other trained health professional based on co-participant interview, as described by the training video. (This is not to be completed by the participant as a paper-and-pencil self-report.) For information on NPI-Q Interviewer Certification, see UDS Coding Guidebook for Form B5 . Check only one box for each category of response.									
mem 0=No For e	Please answer the following questions based on <u>changes</u> that have occurred since the participant first began to experience memory (i.e., cognitive) problems. Select 1=Yes <u>only</u> if the symptom(s) has been present <u>in the last month</u>. Otherwise, select 0=No. (NOTE: for the UDS, please administer the NPI-Q to all participants.) For each item marked 1=Yes, rate the SEVERITY of the symptom (how it affects the participant): 1= Mild (noticeable, but not a significant change) 2= Moderate (significant, but not a dramatic change) 3= Severe (very									
	ed or prominent; a dramatic change)									
1. NP	ICO-PARTICIPANT: \square_1 Spouse \square_2 Child \square_3 Other (SPECIFY):									
			Yes	No	Unk		Mild	SEVE Mod		Unk
2.	Delusions – Does the patient have false beliefs, such as thinking that others are stealing from him/her or planning to harm him/her in some way?	2a.	□ 1	□о	□ 9	2b.	□ 1	□ 2	□ 3	<u> </u>
3.	Hallucinations – Does the patient have hallucinations such as false visions or voices? Does he or she seem to hear or see things that are not present?	3a.		О	□ 9	3b.		□ 2	□ 3	<u> </u>
4.	Agitation/Aggression – Is the patient resistive to help from others at times, or hard to handle?	4a.	□ 1	О	<u> </u>	4b.	□ 1		□ 3	<u> </u>
5.	Depression/Dysphoria – Does the patient seem sad or say that he/ she is depressed?	5a.	□ 1	О	<u> </u>	5b.	□ 1		□ 3	<u> </u>
6.	Anxiety – Does the patient become upset when separated from you? Does he/she have any other signs of nervousness such as shortness of breath, sighing, being unable to relax, or feeling excessively tense?	6a.	□ ₁	О	<u> </u>	6b.	□ ₁	□ ₂	Пз	□ 9
7.	Elation/Euphoria – Does the patient appear to feel too good or act excessively happy?	7a.	□ 1	О	<u> </u>	7b.	□ ₁	2	□ 3	□ 9
8.	Apathy/Indifference – Does the patient seem less interested in his/her usual activities or in the activities and plans of others?	8a.	□ 1	О	<u> </u>	8b.	□ 1	□ 2	Пз	<u> </u>
9.	Disinhibition – Does the patient seem to act impulsively, for example, talking to strangers as if he/she knows them, or saying things that may hurt people's feelings?	9a.		О	□ 9	9b.	□ 1	\square_2	Пз	□ 9
10.	Irritability/Lability – Is the patient impatient and cranky? Does he/she have difficulty coping with delays or waiting for planned activities?	10a.	□ 1	О	<u></u> 9	10b.	□ 1	□ 2	Пз	<u></u> 9
11.	Motor disturbance – Does the patient engage in repetitive activities such as pacing around the house, handling buttons, wrapping string, or doing other things repeatedly?	11a.	□ 1	О	□ 9	11b.		□ 2	□ 3	<u></u> 9
12.	Nighttime behaviors – Does the patient awaken you during the night, rise too early in the morning, or take excessive naps during the day?	12a.	□ 1	По	9	12b.		□ 2	□ 3	<u></u> 9
	Appetite/Eating – Has the patient lost or gained weight, or had a change in the type of food he/she likes?	13a.	□ 1	О	<u> </u>	13b.	□ 1	2	□ 3	<u> </u>
Copyrig	ht© Jeffrey L. Cummings, MD. Reproduced by permission.									



Form B6: BEHAVIORAL ASSESSMENT — Geriatric Depression Scale (GDS)¹

ADRC: _	PTID:	/	Visit #:	initials:					
Langua 1 En	glish	mpaired npaired nursing home on visit	95=Physic	ompleted reason): al problem iive/behavioral problem refusal					
	INSTRUCTIONS : This form is to be completed by the clinician or other trained health professional, based on participant response. For additional clarification and examples, see UDS Coding Guidebook for Form B6 . Check only one answer per question.								
	Check this box and enter "88" below for the Total GDS Score if and only if the participant: 1.) does not attempt the GDS, or 2.) answers fewer than 12 questions.								
Instruct the participant : "In the next part of this interview, I will ask you questions about your feelings. Some of the questions I will ask you may not apply, and some may make you feel uncomfortable. For each question, please answer "yes" or "no," depending on how you have been feeling in the past week, including today ."									
			Yes	No	Did not answer				
1.	Are you basically satisfied with your life?		О	□ 1	9				
2.	2. Have you dropped many of your activities and interests?			□ ₀	9				
3.	Do you feel that your life is empty?		□ 1	□0	9				
4.	4. Do you often get bored?			□ ₀	9				
5.	Are you in good spirits most of the time?		□ ₀	□ 1	<u> </u>				
6.	Are you afraid that something bad is goi	ng to happen to you?		□ ₀	9				
7.	Do you feel happy most of the time?		□ ₀	□ 1	<u> </u>				
8.	Do you often feel helpless?		□ ₁	\square_0	<u> </u>				
9.	Do you prefer to stay at home, rather tha	n going out and doing new things?	□ ₁	\square_0	<u> </u>				
10.	Do you feel you have more problems wit	h memory than most?		\square_0	9				
11.	Do you think it is wonderful to be alive n	ow?	□ ₀	□ 1	9				
12.	Do you feel pretty worthless the way you	are now?		□ ₀	9				
13.	Do you feel full of energy?		О	□ 1	<u> </u>				
14.	Do you feel that your situation is hopeles	ss?	□ 1	□ ₀	<u></u> 9				
15.	Do you think that most people are bette	r off than you are?		О	<u></u> 9				
16.	Sum all checked answers for a Total GDS	Score (max score = 15; did not complete :	= 88)						

1Sheikh Jl, Yesavage JA. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clinical Gerontology: A Guide to Assessment and Intervention 165–173, NY: The Haworth Press, 1986. Reproduced by permission of the publisher.

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org



Form B7: FUNCTIONAL ASSESSMENT – NACC Functional Assessment Scale (FAS1)

ADRC:	PTID:	Form date://	Visit #: initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired	Key (not completed reason):
□₁ English	□ 1 In-person	2=Too physically impaired	95=Physical problem
☐2 Spanish	☐ 2 Remote (reason):	3=Homebound or nursing home	96=Cognitive/behavioral problem
	□1 Telephone □2 Video	4=Refused in-person visit	97=Other
	□ o Not completed (reason):	5=Other	98=Verbal refusal

INSTRUCTIONS: This form is to be completed by the clinician or other trained health professional, based on information provided by the co-participant. For further information, see <u>UDS Coding Guidebook for Form B7</u>. Indicate the level of performance for each activity by checking the one appropriate response.

In the past four weeks, did the participant have difficulty or need help with:	Not applicable (e.g., never did)	Normal	Has difficulty, but does by self	Requires assistance	Dependent	Unknown
1. Writing checks, paying bills, or balancing a checkbook	□8	О	□ 1	□ 2	□ 3	<u></u> 9
2. Assembling tax records, business affairs, or other papers	□8	О	□ 1	\square_2	□ 3	<u></u> 9
3. Shopping alone for clothes, household necessities, or groceries	□8	О	<u> </u>	<u>2</u>	□ 3	<u></u> 9
4. Playing a game of skill such as bridge or chess, working on a hobby	□8	О	□ 1	<u></u>	3	<u></u> 9
5. Heating water, making a cup of coffee, turning off the stove	□8	О	□ 1	□ 2	Пз	<u></u> 9
6. Preparing a balanced meal	□8	О	□ 1	\square_2	□ 3	9
7. Keeping track of current events	□8	О	□ 1	2	Пз	<u></u> 9
8. Paying attention to and understanding a TV program, book, or magazine	□8	□0	□ 1	□ ₂	□ 3	□ 9
9. Remembering appointments, family occasions, holidays, medications	□ 8	□0	<u> </u>	□ ₂	□ 3	<u></u> 9
10. Traveling out of the neighborhood, driving, or arranging to take public transportation	□8	□0	□ 1	\square_2	□ ₃	□ 9

'Adapted from table 4 of Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities of older adults in the community. J Gerontol 37:323 – 9, 1982. Copyright© $1982. \, The \, Gerontological \, Society \, of \, America. \, Reproduced \, by \, permission \, of \, the \, publisher. \,$

ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org



Form B8: EVALUATION FORM – Neurological Examination Findings

ADRC:	PTID:	F	orm date:	// Vis	Examin it #: initials:					
□₁ Eng	Language: □ 1 English □ 2 Spanish □ 2 Video □ 3 Homebound or nursing home 4=Refused in-person visit 5=Other									
INSTRUCTIONS: This form should be completed by a clinician with experience in performing a comprehensive neurologic examination, assessing the presence/absence of neurological signs, and rating the degree of any abnormalities. Additionally, the clinician should have experience in completing each of the assessment measures associated with the gateway questions if any key neurologic findings are present. For additional clarification and examples, see UDS Coding Guidebook for Form B8 . Check only One box per question .										
Secti	Section 1 – Examiner & examination questions									
2. W	 Which of the following was completed on this participant? 0 No neurologic examination (END FORM HERE) 1 Comprehensive neurologic examination as suggested in the UDS Coding Guidebook 2 Focused or partial neurologic examination performed in-person 3 Focused or partial neurologic examination performed via video Were there abnormal neurological exam findings? 0 No abnormal findings (END FORM HERE; If this box is checked, all items will default to 0 = Absent in the database) 									
	1 Yes		. a, a a		o database,					
Secti	on 2 – Specific clinical findings									
Secti	ion 2A – Parkinsonian signs									
3. [in	0 No abnormal signs in this section are present the database) 1 Yes (IF YES – complete questions 3a–3n and considerally Not assessed (SKIP TO SECTION 2B; If this box is	er completing	additional meas	ures as described on pag	e 3)	0 = Absent				
FIND	ING:	Absent	Focal or Unilateral	Bilateral & Largely Symmetric	Bilateral & Largely Asymmetric	Not Assessed				
3a.	Slowing of fine motor movements	По	□ 1	2	3	□8				
3b.	Limb tremor at rest	По	□ 1	2	□ 3	□8				
3с.	Limb tremor - postural	О	□ 1	_2	3	□8				
3d.	Limb tremor - kinetic	О	□ 1	_2	□ 3	□8				
3e.	Limb rigidity - arm	О	□ 1	□ 2	\square_3	□8				
3f.	Limb rigidity - leg	О	□ 1	_2	3	□8				
3g.	Limb dystonia - arm	□ ₀	□ 1	2	3	□8				
3h.	Limb dystonia - leg	□ ₀	□1	2	□ 3	□8				
3i.	Chorea	О	□ 1	2	3	□8				

ALZHEIMER'S COORDINATING CENTER naccdata.org

Secti	on 2 – Specific clinical findings						C	ontinued
Secti	ion 2A – Parkinsonian signs							
FIND	ING:				Absent	Present	Not A	ssessed
3j.	Decrement in amplitude of fine motor moven	nents			По	□ ₁		
3k.	Axial rigidity				По	□ 1		3 8
31.	Postural instability				По	□ 1		_ 8
3m.	Facial masking				По	□ 1		
3n.	Stooped posture				О	□ 1		3 8
Secti	ion 2B – Cortical/pyramidal/other signs							
4.	Jo No abnormal signs in this section are present in the database)	(SKIP TO S	ECTION 2C; If ti	his box is ch	ecked, Q4a th	rough Q4q will	default to	0=Absent
	1 Yes (IF YES – complete questions 4a–4q and conside							
	8 Not assessed (SKIP TO SECTION 2C; If this box is	checked, Q4a	ı through Q4q w	ill default to	8 = Not Asses			
FIND	ING:	Absent	Focal or Unilateral		l & Largely metric	Bilateral & Asymm		Not Assessed
4a.	Limb apraxia	По	□ 1	[□ 8
4b.	Face or limb findings in UMN distribution*	О	□ ₁	[□ ₃		□8
4c.	Face or limb findings in an LMN distribution*	О	□ 1	[\square_2	□ 3		□8
4d.	Visual field cut	О	1	[□ ₃		□ 8
4e.	Limb ataxia	О	□ 1	[\square_2	□ 3		□ 8
4f.	Myoclonus	□0	□ 1			□ 3		□8
FIND					Absent	Present	Not A	ssessed
4g.	Unilateral Somatosensory loss (localized to the b localized to the spinal cord or peripheral nerves)	rain; disregar	d sensory chang	es	□0	□1		8
4h.	Aphasia (disregard complaints of mild dysnomia if not viewe	ed as reflecting	a clinically significa	ant change)	О	□ 1		8
4i.	Alien limb phenomenon				О	□1		8
4j.	Hemispatial neglect				О	□ 1		8
4k.	Prosopagnosia				О	□1		8
41.	II. Simultanagnosia				О	□ ₁		8
4m.	n. Optic ataxia				О	□ 1		3 8
4n.	n. Apraxia of gaze				О	□ 1		8
40.	Vertical +/- horizontal gaze palsy**				О	□ ₁		3 8
4p.	Dysarthria*				О	□ ₁		3 8
4q.	Apraxia of speech				О	□ ₁		8
	ndings could include weakness in a pyradmidal pa ndings could include weakness due to neuromuscu							as

Form date:

Visit #:

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

**Do not mark Present if only reduction of upgaze is present.

could be consistent with a cerebrovascular insult or with a degenerative disorder such as ALS, PLS, SMA, PSP, CBS, etc.

Participant ID: Form date:	/ / Visit #:
Section 2 – Specific clinical findings Section 2C – Gait	continued
5. O No abnormal signs in this section are present (END FOR 1 Yes (IF YES - complete question 5a and consider completing adds 8 Not assessed (END FORM HERE)	
5a. Finding: ☐ 1 Hemiparetic gait (spastic) ☐ 2 Foot drop gait (lower motor neuron) ☐ 3 Ataxic gait ☐ 4 Apractic magnetic gait ☐ 5 Hypokinetic/parkinsonian gait ☐ 6 Antalgic gait	7 Other (SPECIFY):
Section 2D – Additional measures	
There are several additional clinical measures to consider for completion depending on the findings and the suspicion of the clinical syndrome; these include, but are not limited to, the following: a) If there are any features of a movement disorder (e.g., bradykinesia, tremor, rigidity, postural instability, etc.): Consider completing Form B3 UPDRS, or the MDS-UPDRS b) If there are any features of ALS (e.g., upper motor neuron dysfunction and/or lower motor neuron dysfunction): Consider completing the ALSFRS-R c) If there are any features of PSP- Richardson's syndrome (e.g., parkinsonism, postural instability, supranuclear gaze palsy, etc.): Consider completing the PSPRS	d) If there are any features of corticobasal syndrome (e.g., limb rigidity, limb apraxia, myoclonus, dystonia, corticol sensory loss, alien limb phenomenon, etc.): Consider completing the PSPRS and/or the CBFS e) If there are any features of complex visual processing dysfunction (e.g. hemineglect, visual agnosia, simultanagnosia, optic ataxia, ocular apraxia, apraxia of eyelid opening, etc.): Consider completing a standardized measure assessing PCA f) If there are any features of aphasia or apraxia of speech (e.g., NIH Stroke Scale, Progressive Aphasia Severity Scale, Western Aphasia Battery, etc.): Consider completing a standardized measure assessing speech and language g) If there are clinical and/or imaging findings suggesting a vascular contribution to the clinical presentation: Consider completing NIH Stroke Scale, Hachinski Ischemic Scale, etc.
Section 2E – Glossary of abbreviations	
ALS = Amyotrophic Lateral Sclerosis	
ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale	z–Revised
CBS = Corticobasal Syndrome	
CBFS = Cortical Basal ganglia Functional Scale	
LMN = Lower Motor Neuron	
MDS-UPDRS = Movement Disorders Society - Unified Parkinson's	Disease Ratina Scale
PCA = Posterior Cortical Atrophy	2.000.00 1.00.01.0
PLS = Primary Lateral Sclerosis	
PSP = Progressive Supranuclear Palsy	
PSPRS = Progressive Supranuclear Palsy Rating Scale	
SMA = Spinal Muscular Atrophy	
UMN = Upper Motor Neuron	
UPDRS = Unified Parkinson's Disease Rating Scale	



Form B9: Clinician Judgment of Symptoms

ADRC:	PTID:	Form date:/	/ \	/isit #:		itials:		
Langua □1 En □2 Sp	glish □1 In-person	Key (remote reason): 1=Too cognitively in 2=Too physically im 3=Homebound or r 4=Refused in-perso 5=Other	npaired nursing home					
or co- estim see <u>U</u>	INSTRUCTIONS: This form is to be completed by the clinician. Questions below are not intended for direct administration to participant or co-participant. For all questions the clinician must use their best judgment about whether symptoms are present and make their estimate when symptoms began based on information from participant and co-participant. For additional clarification and examples, see UDS Coding Guidebook for Form B9. Check only one box per question.							
	ion 1 – Changes across domair	ns .						
	ted by participant							
	baseline prior to onset of current syndron	any cognitive domain (relative to stable pe)?	□0 No □1 Yes			e assessed / impaired		
	Does the <u>participant</u> report a change in baseline prior to onset of current syndron		□ o No □ 1 Yes			e assessed/ impaired		
	Does the <u>participant</u> report the develor neuropsychiatric/behavioral symptoms of current syndrome)?		□ 0 No □ 1 Yes			e assessed/ impaired		
Repor	ted by co–participant							
	Does the <u>co-participant</u> report a decline stable baseline prior to onset of current sy		□ o No □ 1 Yes	□8 The	ere is no c	o-participant		
	Does the <u>co-participant</u> report a chang baseline prior to onset of current syndron	e in any motor domain (relative to stable ne)?	□ o No □ 1 Yes	□8 The	ere is no c	o-participant		
	Does the <u>co-participant</u> report the deven neuropsychiatric/behavioral symptoms of current syndrome)?		0 No 1 Yes	□8 The	ere is no c	o-participant		
Repor	ted by clinician							
	Does the participant have any neuropsy cognitive domains, or changes in any m	chiatric/behavioral symptoms, decline in otor domains?	any	0 No	-	RM HERE)		
		rpe of clinically meaningful symptoms or a following the medical history interview wi						
Sect	ion 2 – Cognitive impairment							
Consi	der if the participant currently is meani	ngfully impaired, relative to stable basel i	ine prior to o	nset of o	current sy	<u>/ndrome</u> :		
	Based on the clinician's judgment, is the impairment in cognition?	participant currently experiencing mean	ingful	0 No		QUESTION 11)		
9.	9. Indicate whether the participant is meaningfully impaired in the following cognitive domains or has fluctuating cognition:							
Co	gnitive			No	Yes	Unknown		
9a	 Memory — Does the participant for statements, or misplace things more 	get conversations or dates, repeat questio than usual?	ns or	□ ₀	□ 1	<u></u> 9		
9b		have trouble knowing the day, month, an ell, get lost in familiar locations, or not rec		О	□ 1	□ 9		
90		nning, and problem-solving) — Does the ities like trips, financial transactions, partic		□o	□ 1	<u> </u>		

9d. Language — Does the participant have hesitant speech, have trouble finding words, use inappropriate words without self-correction, or have trouble with speech comprehension? 9e. Visuospatial function — Does the participant have difficulty interpreting visual stimuli or finding their way around in familiar environments? 9f. Attention/concentration — Does the participant have a short attention span or limited ability to concentrate? Are they easily distracted? 9g. Fluctuating cognition — Does the participant exhibit pronounced variation in attention	nknown g
 9d. Language — Does the participant have hesitant speech, have trouble finding words, use inappropriate words without self-correction, or have trouble with speech comprehension? 9e. Visuospatial function — Does the participant have difficulty interpreting visual stimuli or finding their way around in familiar environments? 9f. Attention/concentration — Does the participant have a short attention span or limited ability to concentrate? Are they easily distracted? 9g. Fluctuating cognition — Does the participant exhibit pronounced variation in attention and alertness, noticeably over hours or days—for example, long lapses or periods of staring into space, or times when their ideas have a disorganized flow? 9h. Other (SPECIFY):	<u></u> 9
or finding their way around in familiar environments? 9f. Attention/concentration — Does the participant have a short attention span or limited ability to concentrate? Are they easily distracted? 9g. Fluctuating cognition — Does the participant exhibit pronounced variation in attention and alertness, noticeably over hours or days—for example, long lapses or periods of staring into space, or times when their ideas have a disorganized flow? 9h. Other (SPECIFY):	<u> </u>
ability to concentrate? Are they easily distracted? 9g. Fluctuating cognition — Does the participant exhibit pronounced variation in attention and alertness, noticeably over hours or days—for example, long lapses or periods of staring into space, or times when their ideas have a disorganized flow? 9h. Other (SPECIFY):	
and alertness, noticeably over hours or days—for example, long lapses or periods of staring into space, or times when their ideas have a disorganized flow? 9h. Other (SPECIFY):	<u> </u>
9i. If any of the cognitive symptoms in 9a-9h are present, at what age did they begin? (The clinician must use their best judgment to estimate an age of onset. If multiple symptoms with different ages of onset are identified, denote the age of the earliest symptom.) 10. Mode of onset of cognitive impairment: Indicate the mode of onset for the most prominent cognitive problem that is causing the participant's complaints and/or affecting the participant's [] Gradual [] 4 Other (SPECIFY): [] 3 Abrupt [] 99 Unknown Section 3 – Neuropsychiatric symptoms and behavioral changes Consider if the participant manifests – in the last month – clinically meaningful neuropsychiatric symptoms or change in behavioral state prior to the onset of the current syndrome). Clinically meaningful of the current syndrome.	<u></u> 9
(The clinician must use their best judgment to estimate an age of onset. If multiple symptoms with different ages of onset are identified, denote the age of the earliest symptom.) 10. Mode of onset of cognitive impairment: Indicate the mode of onset for the most prominent cognitive problem that is causing the participant's complaints and/or affecting the participant's function. Section 3 – Neuropsychiatric symptoms and behavioral changes Consider if the participant manifests – in the last month – clinically meaningful neuropsychiatric symptoms or change in behavioral state prior to the onset of the current syndrome). Clinically meaningful of the current syndrome.	
Indicate the mode of onset for the <u>most prominent</u> cognitive problem that is causing the participant's complaints and/or affecting the participant's 2 Subacute 3 Abrupt 99 Unknown 3 Abrupt 99 Unknown 3 Abrupt 199 Unknown 4 Subacute 199 Unknown 5 Section 3 - Neuropsychiatric symptoms and behavioral changes 6 Consider if the participant manifests - in the last month - clinically meaningful neuropsychiatric symptoms or change in behavioral state prior to the onset of the current syndrome). Clinically meaningful of the current syndrome.	
Consider if the participant manifests – in the last month – clinically meaningful neuropsychiatric symptoms or change in behandler in the last month of the current syndrome. Clinically meaningful of the current syndrome.	
Consider if the participant manifests – in the last month – clinically meaningful neuropsychiatric symptoms or change in behandler in the last month of the current syndrome. Clinically meaningful of the current syndrome.	
refers to symptoms of changes that are evident most days in a given four-week period.	
11. Based on the clinician's judgment, does the participant manifest clinically meaningful neuropsychiatric symptoms or meaningful change in behavior?	STION 14)
12. Specify the phenotype of clinically meaningful neuropsychiatric symptoms or meaningful change in behavior that has manifested <i>in the last month</i> .	ıs
Mood, motivation, and agitation No Yes Unk	
12a. Apathy/withdrawal — Has the participant lost interest in the world around them, lost interest in doing things, or lack motivation for starting new activities?	nknown
12b. Depressed mood — Does the participant seem sad or depressed, or say that they feel sad or depressed?	nknown
12c. Anxiety — Does the participant seem very nervous, worried, or frightened for no apparent reason? Do they seem very tense or fidgety? Do they seem afraid to be apart from caregivers or from others that they trust?	
12d. Euphoria — Does the participant seem too cheerful or too happy for no reason, manifest a persistent and abnormally good mood, or find humor where others do not?	9
12e. Irritability — Does the participant get irritated and easily disturbed? Are their moods very interchangeable? Are they abnormally impatient?	9 9
12f. Agitation — Is the participant easily distressed or angered, or hard to handle, or uncooperative, or resistive to care or to help from others?	□9 □9 □9
12g. If any of the mood–related behavioral changes in 12a–12f are present, at what age did they begin? (The clinician must use their best judgment to estimate an age of onset. If multiple symptoms are identified, denote the age of the earliest symptom.)	

Form date: ____ / ___ / ___ __ __ __

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Particip	ant ID:	Form date: / / / \	/isit #: _					
Section 3 – Neuropsychiatric symptoms and behavioral changes conti								
Psych	osis a	nd impulse control	No	Yes	Unknown			
12h.	Visua stimu	Il hallucinations - Does the participant exhibit visual perceptions without a llus?	□ ₀	□ 1	<u></u> 9			
1	12h1.	IF YES, do their hallucinations include patterns that are not definite objects, such as pixelation of flat uniform surfaces?	□ ₀	□ 1	<u></u> 9			
1	12h2.	IF YES, do their hallucinations include well-formed and detailed images of objects or people, either as independent images or as part of other objects?	О	□ 1	<u></u> 9			
12i.	12i. Auditory hallucinations - Does the participant exhibit auditory perceptions without a stimulus?				<u></u> 9			
	12i1.	IF YES, do the auditory hallucinations include simple sounds like knocks or other simple sounds?	□ ₀	□ 1	<u></u> 9			
	12i2.	IF YES, do the auditory hallucinations include complex sounds like voices speaking words, or music?	□o	□ 1	<u></u> 9			
12j.	exam	sions - Does the participant have fixed, idiosyncratic beliefs that are not true? For ple, insisting that others are trying to harm them or steal from them? Have they said amily members or staff are not who they say they are, or that the house is not their e?	О	<u> </u>	<u></u> 9			
12k.		ession — Does the participant shout angrily, slam doors, attempt to hit or hurt s, or exhibit other verbally or physically aggressive behaviors?	О	□ 1	<u></u> 9			
12l.	prese	of the psychosis and impulse control-related behavioral changes in 12h–12k are int, at what age did they begin? (The clinician must use their best judgment to estimate e of onset. If multiple symptoms are identified, denote the age of the earliest symptom.)						
Perso	nality		No	Yes	Unknown			
12m.		hibition — Does the participant act impulsively without thinking, say things that ot usually done or said in public, or do things that are embarrassing to caregivers or	О	□ 1	□ 9			

	an age of onset. If multiple symptoms are identified, denote the age of the earliest symptom.)							
Perso	Personality					Unknown		
12m.	Disinhibition — Does the participant act impulsively without thinking, say things that are not usually done or said in public, or do things that are embarrassing to caregivers or others, or do they talk personally to strangers or have disregard for personal hygiene?					<u></u> 9		
12n.	Personality change — Does the participant exhibit bizarre behavior or behavior uncharacteristic of the participant, such as unusual collecting, suspiciousness (without delusions), unusual dress, or unusual eating behaviors?				□ 1	<u></u> 9		
120.	Loss	of empathy — Does the participant fail to take others' feelings into account	t?	О	□ 1	<u></u> 9		
12p.	Obsessions and/or compulsions — Does the participant repeatedly and excessively focus on particular ideas or activities, or have they developed new habits, like physical behaviors or stereotypical verbal phrases?			□ ₀		<u></u> 9		
12q.	_	osive anger — Does the participant have a "short fuse"? Do they display expursts of anger or rage?	olosive	По	□ 1	<u></u> 9		
12r.	consi	tance use — Does the participant currently show evidence of excessive umption of recreational, psychoactive, or typically abused substances (substances compared with prior habits, and beyond medical necessity if prescribed subs		□ ₀	□ 1	<u></u> 9		
	12r1.	IF YES, record substance(s) involved: 12r1 (Check all that apply) 12r1 12r1 12r1 12r1 12r1 12r1 12r1	b.	Alcohol Sedative/h Opiate Cocaine Cannabis Other (SPE				
12s.	did tl	y of the personality–related behavioral changes in 12m–12r are present, at whey begin? (The clinician must use their best judgment to estimate an age of on in iple symptoms are identified, denote the age of the earliest symptom.)						

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Sec	tion 3 – Neuropsychiatric symptoms and behavioral changes			continued
REN	sleep	No	Yes	Unknown
12	REM sleep behavior disorder — While sleeping, does the participant appear to repeatedly act out their dreams (e.g., punch or flail their arms, shout, or scream)?	О	□ 1	<u></u> 9
	12t1. IF YES, at what age did the dream enactment behavior begin? (The clinician must use their best judgment to estimate an age of onset.)			
	12t2. Was REM sleep behavior disorder confirmed by polysomnography?	О		<u></u> 9
Oth	er	No	Yes	Unknown
12	Other behavioral changes (SPECIFY):	\square_0	□ ₁	
13.	Overall mode of onset for behavioral changes: 1 Gradual Indicate the mode of onset for the most prominent behavioral problem 2 Subacute	□4 Otl	her (SPEC	IFY):
	that is causing the participant's complaints and/or affecting the participant's function.	□99 Uı	nknown	
Sec	tion 4 – Motor changes			
	ider if the participant currently has meaningful change in motor function that represents a ch line prior to the current syndrome and is potentially due to a disorder affecting the centr			
14.	Based on the clinician's judgment, is the participant currently experiencing any meaningful changes in motor function?	□o No		QUESTION 19)
15.	Indicate whether the participant has meaningful change in motor function:			
Mot	or	No	Yes	Unknown
15	Gait disorder — Has the participant's walking changed, not specifically due to arthritis, injury, or peripheral neuropathy? Are they unsteady, or do they shuffle when walking, have little or no arm-swing, or drag a foot?	□ ₀	<u> </u>	<u></u> 9
15	• Falls — Has the participant had an increase in frequency of falls compared with their stable baseline prior to the current syndrome?	О	□ 1	<u>9</u>
15	Slowness — Has the participant noticeably slowed down in walking, moving, or writing by hand, other than due to an injury or illness?	О	□ 1	<u></u> 9
150	Tremors — Has the participant had rhythmic shaking, especially in the hands, arms, legs, head, mouth, or tongue?	\square_0	□ 1	<u></u> 9
15	Limb weakness — Has the participant noticed a change (abrupt or gradual) in limb function such that an arm and/or leg is weak compared to their prior baseline?	По	□ 1	<u>9</u>
15	Change in facial expression — Has the participant's facial expression changed or become more "wooden," or masked and unexpressive?	□ ₀	□ 1	<u></u> 9
15	Change in speech — Has the participant noted a change in speech (abrupt or gradual) such that speech is slurred, or the ability to articulate the tongue and lips to form words and sentences has declined compared to their baseline?	□ ₀	<u> </u>	<u> </u>
15	If changes in motor function are present in 15a–15g, at what age did they begin? (The clinician must use their best judgment to estimate an age of onset. If multiple symptoms are identified, denote the age of the earliest symptom.)			
16.	Mode of onset for motor changes: ☐ 1 Gradual Indicate the mode of onset for the most prominent motor problem that ☐ 2 Subacute	□4 Otl	her (SPEC	IFY):
	is causing the participant's complaints and/or affecting the participant's 3 Abrupt function.	99 Ui	nknown	
		No	Yes	Unknown
17.	Were changes in motor function suggestive of parkinsonism?	О	□ ₁	<u></u> 9
18.	Were changes in motor function suggestive of amyotrophic lateral sclerosis (ALS) (e.g., changes in muscle strength, or muscle twitches in one or more limbs, or slurred speech)?	□0	□ 1	<u></u> 9

____ Form date: ____ / ___ / ___ / ___ __ __

Sec	tion 5 – Overall course of decline and predominant domain	
19.	Overall course of decline of cognitive/behavioral/motor syndrome:	1 Gradually progressive 2 Stepwise 3 Static 4 Fluctuating 5 Improved 8 Not applicable 9 Unknown
20.	Indicate the <u>predominant</u> domain that was first recognized as changed in the participant:	1 Cognition 2 Behavior 3 Motor function 8 Not applicable

Participant ID: _____ Form date: ___ / ___ / ___ Visit #: __



Form C2: Neuropsychological Battery Scores

ADRC:	PTID:	Form date://		initials:
Language:	Mode:	Key (remote reason): 1=Too cognitively impaired]	
☐1 English	□ 1 In-person	2=Too physically impaired		
☐2 Spanish	☐ 2 Remote (reason):	3=Homebound or nursing home		
	□2 Video	4=Refused in-person visit		
		5=Other		

INSTRUCTIONS: This form is to be completed by ADRC or clinic staff. For test administration and scoring, see <u>Instructions for</u> Neuropsychological Battery, Form C2. Any new participants who enroll in the UDS after the implementation of UDSv4 must be assessed with the new neuropsychological test battery (Form C2 or C2T).

KEY: If the participant cannot complete any of the following exams, please give the reason by entering one of the following codes: 95 / 995 = Physical problem 96 / 996 = Cognitive/behavior problem 97 / 997 = Other problem 98 / 998 = Verbal refusal

Sectio	on 1 — Montreal Cognitive Assessment (M	oCA)	
1a.		O No (If No, enter reason code, 95 – 98): 1 1 Yes (CONTINUE WITH QUESTION 1	
1b.	MoCA was administered:	or clinic 2 In home 3 In person	on — other
1c.	Language of MoCA administration: 1 English	2 Spanish 3 Other (SPECIFY):	
1d.	Participant was unable to complete one or more sec	tions due to visual impairment:	□o No □1 Yes
1e.	Participant was unable to complete one or more sec	tions due to hearing impairment:	□ o No □ 1 Yes
1f.	Total Raw Score — Uncorrected (Not corrected for education or visual/hearing impairment) (Enter 88 if any of the following MoCA items were not adminis		(0-30, 88)
1g.	Visuospatial/executive — Trails		(0-1, 95-98)
1h.	Visuospatial/executive — Cube		(0-1, 95-98)
1i.	Visuospatial/executive — Clock contour		(0-1, 95-98)
1j.	Visuospatial/executive — Clock numbers		(0-1, 95-98)
1k.	Visuospatial/executive — Clock hands		(0-1, 95-98)
1l.	Language — Naming		(0-3, 95-98)
1m.	Memory — Registration (two trials)		(0-10, 95-98)
1n.	Attention — Digits		(0 –2, 95-98)
10.	Attention — Letter A		(0-1, 95-98)
1p.	Attention — Serial 7s		(0 –3, 95-98)
1q.	Language — Repetition		(0-2, 95-98)
1r.	Language — Fluency		(0-1, 95-98)
1s.	Abstraction		(0-2, 95-98)
1t.	Delayed recall — No cue		(0-5, 95-98)
1u.	Delayed recall — Category cue		(0-5; 88=Not applicable)
1v.	Delayed recall — Recognition		(0-5; 88=Not applicable)
1w.	Orientation — Date		(0-1, 95-98)
1x.	Orientation — Month		(0-1, 95-98)
1y.	Orientation — Year		(0-1, 95-98)
1z.	Orientation — Day		(0-1, 95-98)
1aa.	Orientation — Place		(0-1, 95-98)
1bb.	Orientation — City		(0 –1, 95-98)

Participa	nt ID: / / / V	isit #:
Sectio	n 2 — Administration of the remainder of the battery	
2a.	The tests following the MoCA were administered: \Box 1 In ADRC or clinic \Box 2 In home	☐ 3 In person — other
2b.	Language of test administration: 1 English 2 Spanish 3 Other (SPECIFY):	
Sectio	n 3 — Craft Story 21 Recall (Immediate)	
3a.	Total story units recalled, verbatim scoring	(0 –44, 95-98)
3b.	(If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 4a.) Total story units recalled, paraphrase scoring	(0-25)
Section	n 4 — Benson Complex Figure Copy	
	Total score for copy of Benson figure (If test not completed, enter reason code, 95–98)	(0-17, 95-98)
Sectio	n 5 — Number Span Test: Forward	
5a.	Number of correct trials (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 6a.)	(0-14, 95-98)
5b.	Longest span forward	(0, 3-9)
Sectio	n 6 — Number Span Test: Backward	
ба.	Number of correct trials (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 7a.)	(0 –14, 95-98)
6b.	Longest span backward	(0, 2-8)
Sectio	n 7 — Category Fluency	
7a.	Animals: Total number of animals named in 60 seconds (If test not completed, enter reason code, 95–98)	(0-77, 95-98)
7b.	Vegetables: Total number of vegetables named in 60 seconds (If test not completed, enter reason code, 95–98)	(0 -77, 95-98)
Sectio	n 8 — Trail Making Test	
8a.	PART A: Total number of seconds to complete (if not finished by 150 seconds, enter 150) (If test not completed, enter reason code, 995–998, and SKIP TO QUESTION 8b. .)	(0 -150, 995-998)
	8a1. Number of commission errors	(0-40)
	8a2. Number of correct lines	(0-24)
8b.	PART B: Total number of seconds to complete (if not finished by 300 seconds, enter 300) (If test not completed, enter reason code, 995–998, and SKIP TO QUESTION 9a.)	(0-300, 995-998)
	8b1. Number of commission errors	(0 -40)
	8b2. Number of correct lines	(0-24)
Sectio	n 9 — Benson Complex Figure Recall	
9a.	Total score for drawing of Benson figure following 10- to 15-minute delay (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 10a.)	(0 –17, 95-98)
9b.	Recognized original stimulus from among four options?	□ o No □ 1 Yes

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

Participa	nt ID: / / V	isit #:
Sectio	n 10 — Craft Story 21 Recall (Delayed)	
	Total story units recalled, verbatim scoring	
10a.	(If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 11a.)	(0 –44, 95-98)
10b.	Total story units recalled, paraphrase scoring	(0-25)
10c.	Delay time (minutes) (99=Unknown)	(0 –85 minutes)
10d.	Cue ("boy") needed	□0 No □1 Yes
Sectio	n 11 — Verbal Fluency: Phonemic Test	
11a.	Number of correct F-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 11d.)	(0 -40, 95-98)
11b.	Number of F-words repeated in 1 minute	(0-15)
11c.	Number of non-F-words and rule violation errors in 1 minute	(0-15)
11d.	Number of correct L-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 12.)	(0-40, 95-98)
11e.	Number of L-words repeated in one minute	(0-15)
11f.	Number of non-L-words and rule violation errors in 1 minute	(0-15)
11g.	TOTAL number of correct F-words and L-words	(0-80)
11h.	TOTAL number of F-word and L-word repetition errors	(0-30)
11i.	TOTAL number of non-F/L words and rule violation errors	(0-30)
12. V	Which verbal learning test was 1 Rey AVLT	2 CERAD
	ddministered? (CÓMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	(SKIP TO SECTION 14)
а	dministered? (COMPLETE SECTIONS 12 & 13,	(SKIP TO SECTION 14)
Sectio	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	(SKIP TO SECTION 14)
Sectio	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate)	# of intrusions
Section Total nu	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions	
Sectio Total nu Trial	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imper of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98)	# of intrusions
Section Total nu Trial Trial 1	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.)	# of intrusions 12b (No limit)
Section Total nu Trial Trial 1 Trial 2	idministered? (COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15) In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15)	# of intrusions 12b (No limit) 12d (No limit)
Sectio Total nu Trial Trial 1 Trial 2 Trial 3	in 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4	in 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5	in 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12i (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit)
Sectio Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6	COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit)
Sectio Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6	COMPLETE SECTIONS 12 & 13, SKIP SECTIONS 12 & 13, SKIP SECTIONS 14 & 15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12i (0-15) 12i (0-15) 12i (0-15) 12i (0-15) 12m (0-15) 12m (0-15) 12m (0-15) Total delayed recall	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a.	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12l (0-15)	# of intrusions 12b (No limit) 12d (No limit) 12f (No limit) 12h (No limit) 12j (No limit) 12l (No limit) 12n (No limit) (0-15, 95-98)
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a. 13b.	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall 12a (0-15, 95-98) (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) 12c (0-15) 12e (0-15) 12g (0-15) 12i (0-15) 12k (0-15) 12k (0-15) 12m (0-15) 12m (0-15) Total delayed recall (If test was not completed, enter reason code, 95-98. SKIP TO QUESTION 16a.) Intrusions	# of intrusions 12b
Section Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a. 13b. 13c.	In 12 — Rey Auditory Verbal Learning (Immediate) Imber of words correctly recalled and number of intrusions Total recall	# of intrusions 12b
Total nu Trial Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 List B Trial 6 Section 13a. 13b. 13c. 13d. 13e.	In 12 — Rey Auditory Verbal Learning (Immediate) Import of words correctly recalled and number of intrusions Total recall	# of intrusions 12b

NATIONAL ALZHEIMER'S COORDINATING CENTER | naccmail@uw.edu | naccdata.org

Participa	nt ID:	Form date:	/ /	′	v	isit #:		
Sectio	n 14 — CERAD Verba	al Learning (Immedia	ate)					
	List Memory Task: Total nu	ımber of words correctly re	ecalled and numbe					
Trial	Total recall			Can't read	d	# of intru	ısions	
Trial 1	14a (0-10, 95-98) (If test was not completed, en	ter reason code, 95-98. SKIP TC	QUESTION 16a.)	14b	_ (0-10)	14c	(No limit)	
Trial 2	14d (0-10)						(No limit)	
Trial 3	14g (0-10)			14h	_ (0-10)	14i	_ (No limit)	
Sectio	n 15 — CERAD Verba	al Learning (Delayed	Recall and Re	cognition)			
15a.	Delay time (minutes) (99	=Unknown)				(0-	-85 minutes)	
15b.		number of words correctly eason code, 95-98, and SKIP TC				(0	-10, 95-98)	
15c.	J6 Word List Recall: Total	number of intrusions				(N	o limit)	
15d.	J7 Word List Recognition: (If test not completed, enter re	: Total YES correct eason code, 95-98, and SKIP TC	QUESTION 16a.)			(0	-10, 95-98)	
15e.	J7 Word List Recognition:	:Total NO correct				(0-	-10, 95-98)	
Sectio	n 16 — Multilingual	Naming Test (MINT)						
16a.	Total score	eason code, 95–98, and SKIP T o				(0	-32, 95-98)	
16b.	. Total correct without semantic cue				(0-32)			
16c.	z. Semantic cues: Number given					(0-	-32)	
16d.	d. Semantic cues: Number correct with cue (88 = Not applicable)				(0-32, 88)			
16e.	Phonemic cues: Number	given				(0-32)		
16f.	Phonemic cues: Number	correct with cue (88 = Not o	applicable)			(0	-32, 88)	
Sectio	n 17 — Overall appr	aisal						
17a.	Per the clinician (e.g., neubehavioral neurologist, oclinician), based on the Uexamination, the particip deemed:	r other suitably qualified IDS neuropsychological	1 Better than r 2 Normal for a 3 One or two t 4 Three or mo 0 Clinician una	ige test scores ar ire scores are	e abnorm abnorma	al or lower tl	han expected	
Sectio	n 18 — Validity of pa	articipant's response						
	ecord your impression of world in adjudication and da					s. It can be c	lifficult to judge, but	
18a.	How valid do you think the participant's responses are?	1 Very valid, probably 2 Questionably valid, p 3 Invalid, probably ina	oossibly inaccurate	e indication o	f particip	ant's cognit	ive abilities	
18b.	What makes this participant's responses less valid? (Check all that apply)	18b1.	or disinterest ues assistance					
						_		

INITIAL VISIT PACKET

UNIFORM DATA SET (UDS) VERSION 4.0



Form C2T: Neuropsychological Battery Scores for T-cog

ADRC:	PTID:	Form date://	Examiner's Visit #: initials:
Language □1 Engli □2 Span	sh	Key (remote reason): 1=Too cognitively impaired 2=Too physically impaired 3=Homebound or nursing home 4=Refused in-person visit 5=Other	
Neurop assessed KEY: If	sychological Battery, Form C2T. Any n I with the new neuropsychological test ba the participant cannot complete any of	ADRC or clinic staff. For test administration and scoring ew participants who enroll in the UDS after the impler ttery (Form C2 or C2T). the following exams, please give the reason by ente ehavior problem 97 / 997 = Other problem 98 / 998	nentation of UDSv4 must be ering one of the following codes:
Sectio	n 1 — Montreal Cognitive Asse	essment (MoCA) Blind	
1a.	Was any part of the MoCA administere	d?	
1b.	Language of MoCA administration:	1 English 2 Spanish 3 Other (SPECIFY):	
1c.	Participant was unable to complete on	e or more sections due to hearing impairment:	□ o No □ 1 Yes
1d.	Total Raw Score — Uncorrected (Not corrected for education or visual/heari (Enter 88 if any of the following MoCA items v		(0-22, 88)
1e.	Attention — Digits		(0 -2, 95-98)
1f.	Attention — Letter A		(0-1, 95-98)
1g.	Attention — Serial 7s		(0 –3, 95-98)
1h.	Language — Repetition		(0-2, 95-98)
1i.	Language — Fluency		(0-1, 95-98)
1j.	Abstraction		(0-2, 95-98)
1k.	Delayed recall — No cue		(0-5, 95-98)
1l.	Delayed recall — Category cue		(0 –5; 88=Not applicable)
1m.	Delayed recall — Recognition		(0 –5; 88=Not applicable)
1n.	Orientation — Date		(0-1, 95-98)
10.	Orientation — Month		(0-1, 95-98)
1p.	Orientation — Year		(0 –1, 95-98)
1q.	Orientation — Day		(0-1, 95-98)
1r.	Orientation — Place		(0-1, 95-98)
1s.	Orientation — City		(0 –1, 95-98)
Sectio	n 2 — Administration of the re	mainder of the battery	
2a.	Language of test administration:	1 English 2 Spanish 3 Other (SPECIFY): _	
Sectio	n 3 — Craft Story 21 Recall (Im	mediate)	
3a.	Total story units recalled, verbatim sco (If test not completed, enter reason code, 95–		(0-44, 95-98)

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org

3b. Total story units recalled, paraphrase scoring

Participa	int ID:	Form date:		/isit #:
Sectio	on 4 — Number Span	Test: Forward		
4a.	Number of correct trials (If test not completed, enter r	eason code, 95–98, and SKIP T o	O QUESTION 5a.)	(0 –14, 95-98)
4b.	Longest span forward			(0, 3-9)
Sectio	on 5 — Number Span	Test: Backward		
5a.	Number of correct trials (If test not completed, enter r	eason code, 95–98, and SKIP T e	O QUESTION 6.)	(0 –14, 95-98)
5b.	Longest span backward			(0, 2-8)
6. W	hich verbal learning te	est was administered?	Rey AVLT (COMPLETE SECTIONS 6 & 13, SKIP SECTIONS 7 & 9)	2 CERAD (COMPLETE SECTIONS 7 & 9, SKIP SECTIONS 6 & 13)
Sectio	on 6 — Rey Auditory	Verbal Learning (Imi	mediate)	
		ecalled and number of intru		
Trial		Total recall		# of intrusions
Trial 1		6a (0-15, 95-98) (If test was not completed, en QUESTION 8a.)	ter reason code, 95-98, and SKIP TO	6b (No limit)
Trial 2		6c (0-15)		6d (No limit)
Trial 3		6e (0-15)		6f (No limit)
Trial 4		6g (0-15)		6h (No limit)
Trial 5		6i (0-15)		6j (No limit)
List B		6k (0-15)		6l (No limit)
Trial 6		6m (0-15)		6n (No limit)
Sectio	on 7 — CERAD Verba	l Learning (Immediat	te)	
J4 Word	l List Memory Task: Total n	umber of words correctly re	ecalled and number of intrusions	
Trial	Total recall			# of intrusions
Trial 1	7a (0-10, 95-98) (If test was not completed, er	nter reason code, 95-98. SKIP TC	O QUESTION 8a and LEAVE 9a-9e BLANK.)	7b (No limit)
Trial 2	7c (0-10)			7d (No limit)
Trial 3	7e (0-10)			7f (No limit)
Sectio	on 8 — Category Flue	ency		
8a.	Animals: Total number o	f animals named in 60 secc eason code, 95–98)	onds	(0 –77, 95-98)
8b.	Vegetables: Total number (If test not completed, enter r	er of vegetables named in 6 eason code, 95–98)	50 seconds	(0 -77, 95-98)

Sectio	n 9 — CERAD Verbal Learning (Delayed Recall and Recognition)	
9a.	Delay time (minutes) (99=Unknown)	(0 –85 minutes)
9b.	J6 Word List Recall: Total number of words correctly recalled (If test not completed, enter reason code, 95-98, and SKIP TO QUESTION 9d.)	(0 -10, 95-98)
9c.	J6 Word List Recall: Total number of intrusions	(No limit)
9d.	J7 Word List Recognition: Total YES correct (If test not completed, enter reason code, 95-98, and SKIP TO QUESTION 10a.)	(0 -10, 95-98)
9e.	J7 Word List Recognition: Total NO correct	(0-10, 95-98)
Sectio	n 10 — Oral Trail Making Test (Optional)	
10a.	PART A: Total number of seconds to complete (if not finished by 100 seconds, enter 100) (If test not completed, enter reason code, 995–998. If test was skipped because optional, enter 888. SKIP TO QUESTION 10b.)	(0-100, 888, 995-998)
	10a1. Number of commission errors	(No limit)
	10a2. Number of correct lines	(0-25)
10b.	PART B: Total number of seconds to complete (if not finished by 300 seconds, enter 300) (If test not completed, enter reason code, 995–998. If test was skipped because optional, enter 888. SKIP TO QUESTION 11a.)	(0-300, 888, 995-998)
	10b1. Number of commission errors	(No limit)
	10b2. Number of correct lines	(0-25)
Sectio	n 11 — Craft Story 21 Recall (Delayed)	
11a.	Total story units recalled, verbatim scoring (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 12a.)	(0-44, 95-98)
11b.	Total story units recalled, paraphrase scoring	(0-25)
11c.	Delay time (minutes) (99=Unknown)	(0 –85 minutes)
11d.	Cue ("boy") needed	□ o No □ 1 Yes
Sectio	n 12 — Verbal Fluency: Phonemic Test	
12a.	Number of correct F-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 12d.)	(0 -40, 95-98)
12b.	Number of F-words repeated in 1 minute	(0-15)
12c.	Number of non-F-words and rule violation errors in 1 minute	(0-15)
12d.	Number of correct L-words generated in 1 minute (If test not completed, enter reason code, 95–98, and SKIP TO QUESTION 13a.)	(0 -40, 95-98)
12e.	Number of L-words repeated in one minute	(0-15)
12f.	Number of non-L-words and rule violation errors in 1 minute	(0-15)
12g.	TOTAL number of correct F-words and L-words	(0-80)
12h.	TOTAL number of F-word and L-word repetition errors	(0-30)
12i.	TOTAL number of non-F/L words and rule violation errors	(0-30)

Form date: ____ / ___ / ___ __ __ __

Participant ID:

NATIONAL ALZHEIMER'S COORDINATING CENTER naccmail@uw.edu naccdata.org

Sectio	n 13 — Rey Auditory	Verbal Learning (Delayed Recall and Recognition)	
13a.	Total delayed recall (If test was not completed, en TO QUESTION 14a.)	ter reason code, 95-98. If test was skipped because optional, enter 88. SKIP	(0 –15, 88, 95-98)	
13b.	Intrusions		(No limit)	
13c.	Delay time (minutes) (99	=Unknown)	(0 –85 minutes)	
13d.	Recognition — Total corn	rect	(0-15)	
13e.	Recognition — Total false	e positive	(0-15)	
Sectio	n 14 — Verbal Nami	ng Test (Optional)		
14a.	Total correct without a cu (If test was not completed, en	ue ter reason code, 95-98. If test was skipped because optional, enter 88.)	(0-50, 88, 95-98)	
14b.	Total correct with phone (If test was not completed, en given, enter 88.)	(0 –50, 88, 95-98)		
Sectio	n 15 — Overall appr	aisal		
15a.	a. Per the clinician (e.g., neuropsychologist, behavioral neurologist, or other suitably qualified clinician), based on the UDS neuropsychological examination, the participant's cognitive status is deemed: □ 1 Better than normal for age □ 2 Normal for age □ 3 One or two test scores are abnormal □ 4 Three or more scores are abnormal or lower than expected □ 0 Clinician unable to render opinion			
Sectio	n 16 — Validity of pa	articipant's responses		
Please re	ecord your impression of w	whether hearing or other factors significantly influenced test resul ta analysis to know that such an influence may have been present		
	How valid do you think the participant's responses are? 1 Very valid, probably accurate indication of participant's cognitive abilities (END FORM HERE) 2 Questionably valid, possibly inaccurate indication of participant's cognitive abilities 3 Invalid, probably inaccurate indication of participant's cognitive abilities			
16b.	What makes this participant's responses less valid?	16b1. 1 Hearing impairment 16b2. 1 Distractions 16b3. 1 Interruptions		
	(Check all that apply)	16b4. ☐ 1 Lack of effort or disinterest 16b5. ☐ 1 Fatigue 16b6. ☐ 1 Emotional issues 16b7. ☐ 1 Unapproved assistance 16b8. ☐ 1 Other (SPECIFY):		

Participant ID: _____ Form date: ___ / ___ / ___ Visit #: ___

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org



Form D1a: Clinical Syndrome

ADRC: _	PTID: F	form date://	Examiner's Visit #: initials:					
Langua 1 En	glish							
INSTRUCTIONS: This form is to be completed by the clinician. For additional clarification and examples, see the <u>UDS Coding Guidebook</u> for Form <u>D1a</u> . Check only <u>one</u> box per question.								
1.	 Diagnosis method—responses in this form are based on diagnosis by a: □ 1 Single clinician □ 2 Formal consensus panel □ 3 Other (e.g., Two or more clinicians or other informal group) 							
Sect	ion 1 – Level of impairment – Unimpaired co	gnition/behavior, SCD, I	MCI/MBI, or dementia					
2.	 Does the participant have: Unimpaired cognition (e.g., cognitive performance and functional status (i.e., CDR) judged to be unimpaired)? AND Unimpaired behavior (i.e., the participant does not exhibit behavior sufficient to diagnose MBI – see MBI section starting at Q7) or dementia due to FTLD or LBD and/or FTLD behavior and language domains=0? No (SKIP TO QUESTION 3) 1 Yes (CONTINUE TO QUESTION 2a) Note: For those with longstanding cognitive impairment that does not represent a decline from their usual functioning, consider checking Question 5b for a diagnosis of "Cognitively Impaired, Not MCI/dementia". 							
Subj	ective Cognitive Decline							
2	2a. Does the participant report 1) significant concerns abo AND 2) no neuropsychological evidence of decline AN		0 No (END FORM HERE) 1 Yes					
2	2b. As a clinician, are you confident that the subjective cog meaningful?	nitive decline is clinically	0 No (END FORM HERE) 1 Yes (END FORM HERE)					
Dem	entia criteria							
Partic	irement #1: ipant has cognitive or behavioral (neuropsychiatric) toms that meet <u>all of the following criteria</u> :	Requirement #2: Participant must have imp following domains:	pairment in <u>one* or more</u> of the					
• R • A • II	 Interfere with ability to function as before at work or at usual activities Represent a decline from previous levels of functioning Are not explained by delirium or major psychiatric disorder Include cognitive impairment detected and diagnosed through a combination of: 1) history-taking; 2) objective assessment (bedside or neuropsychological testing) Impaired ability to acquire and remember new information impaired reasoning and handling of complex tasks, poor judgment Impaired ability to acquire and remember new information in paired reasoning and handling of complex tasks, poor judgment Impaired ability to acquire and remember new information in paired reasoning and handling of complex tasks, poor judgment Impaired ability to acquire and remember new information in paired reasoning and handling of complex tasks, poor judgment Impaired single districtions Impaired ability to acquire and remember new information in paired reasoning and handling of complex tasks, poor judgment Impaired single districtions Impaired ability to acquire and remember new information in paired reasoning and handling of complex tasks, poor judgment Impaired reasoning and handling of complex tasks, poor judgment Impaired single districtions Impaired reasoning and handling of complex tasks, poor judgment Impaired single districtions Impaired single districtions Impaired reasoning and handling of complex tasks, poor judgment Impaired single districtions 							
3.	Does the participant meet criteria for dementia?		0 No (CONTINUE TO QUESTION 4) 1 Yes (SKIP TO QUESTION 6a)					

naccmail@uw.edu ALZHEIMER'S COORDINATING CENTER naccdata.org

Participan	t ID: Form date:	/	/		Visit #:		
Section	n 1 – Level of impairment					continued	
MCI cor	re clinical criteria						
Check all	criteria that apply in Q4.						
	4.						
Q4 are ch	e criteria are checked, choose 1=Yes for Q4b. If less than ecked, with the exception of the third MCI criteria <u>alone</u> I <u>ly</u> the third MCI criteria is met in Q4, select 0=No for Q5	, consider a d					
4b.	Does the participant meet all three of the above cri amnestic)?	teria for MC	(amnestic or	=	O No (CONTIN 1 Yes (SKIPTO	UE TO QUESTION 5) QUESTION 6a)	
Cogniti	vely impaired, not MCI/dementia						
impairme	ose of the "Cognitively impaired, not MCI/dementia" of the "Cognitively impaired, not MCI/dementia" of the control of the cont					ce of cognitive	
	l applicable criteria for cognitively impaired, not N			- •			
	1 Evidence of functional impairment (e.g., CDR SB>0 1 Cognitive testing is abnormal but no clinical conce 1 Longstanding cognitive difficulties, not representi 1 remote TBI, other medical condition with clear effects on co	ern or functi ng a decline	onal decline (e	e.g., CDR S	SB=0 and FAS=0)	
If any of t	he criteria in Q5 are met choose 1=Yes for Q5b.						
5b.	Does the participant meet any criteria for cognitive	ly impaired,	not MCI/dem	=	0 No (SKIPTO 1 Yes (SKIPTO		
Affecte	d Domains – Dementia and MCI						
neuropsy	lomains that are impaired at the current visit based o	all others wil	l default to un	impaire	in the NACC da	itabase.	
(not in th	behavior changes: For patients with <i>dementia</i> who have be following MBI section) by marking Q6f as Impaired ext of an MCI (or as an isolated) symptom, consider a	l and skippir	ng the MBI sec	tion (SKIF	PTO Q8). For beh		
						Impaired	
6a.	Memory					□1	
6b.	Language					□ 1	
6c.	Attention					1	
6d.	Executive					1 	
6e.	Visuospatial					1 	
6f.	Behavioral (for participants with dementia only; see N	ИВI for MCI р	articipants)			1 1	
6g.	Apraxia					□ ₁	

Sect	tior	n 1 – Level of impairment	continued	
Mild	Be	havioral Impairment (MBI) core clinical criteria		
• F	Particoperson Symp ate Not e ongs Symp arge	cipant, co-participant, or clinician identifies a change in the participant's affect, motivation, thought content, chality that is clearly different from their usual affect, motivation, thought content, behavior, or personality of the last six months or longer conset (i.e., age > ~50, unless early onset neurodegenerative syndrome is suspected) explained by delirium, other psychiatric disorder by DSM criteria (including recent onset, longstanding or recent and disorder). Standing disorder). Standing disorder with at least one of these: work, interpersonal relationships, social activities ely preserved independence in other functional abilities (no change from prior manner/level of functioning, mal aids or assistance)	urrence of	
7. Does the participant meet criteria for MBI? (If participant meets criteria for dementia an MBI diagnosis is excluded.) 1 Yes (CONTINUE TO QUESTION 8				
	(No	BI affected domains — <u>Select one or more</u> affected domains ote: If "Yes" is indicated in any domain below, the participant should have a corresponding symptom checked on Form B9 — Clin Symptoms, either from among the specific symptoms denoted there, or in "other")	ician Judgment	
			No Yes	
7	7a.	Motivation (e.g., apathy symptoms on Form B9)	□0 □1	
	7b.	Affective regulation (e.g., anxiety, irritability, depression, and/or euphoria symptoms on Form B9)	0	
	7c.	Impulse control (e.g., obsessions/compulsions, personality change, and/or substance abuse symptoms on Form B9)	□0 □1	
7	7d.	Social appropriateness (e.g., disinhibition, personality change, and/or loss of empathy symptoms on Form B9)	0 1	
7	7e.	Thought content/perception (e.g., delusions and/or hallucinations on Form B9)	0 1	
Sec	tio	n 2 – Clinical syndrome		
MCI o cogni Diagn	r ME tive/ lose:	ose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when a BI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information (neuropsychological testing, ideally <u>without</u> reference to biomarker data (which is incorporated into the Ess section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data influenced the clinical diagnosis.	n and tiological	
8.	No	there a predominant clinical syndrome? te that the participant may not meet any clinical criteria or may not have a predominant syndrome instance, this is common for MCI and "impaired, not MCI"). In this case, select "No." 1 Yes	STION 10)	
Select	t the	predominant syndrome as present; all others will default to Absent in the NACC database.	Present	
8	8a.	Amnestic predominant syndrome	1	
8	3b.	Dysexecutive predominant syndrome	□ 1	
:	8c.	Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome)	□ 1	
8	3d.	Primary progressive aphasia (PPA) syndrome:	□ 1	
	8d	11. If present, select one: 1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 4 Primary progressive apraxia of speech 5 PPA other/not otherwise specified		
:	8e.	Behavioral variant frontotemporal (bvFTD) syndrome	□ ₁	
	8f.	Lewy body syndrome	□ ₁	
	81	1. If present, select one: 1 Dementia with Lewy bodies 2 Parkinson's disease 3 Parkinson's disease dementia syndrome		
8	Bg.	Non-amnestic multidomain syndrome, not PCA, PPA, bvFTD, or DLB syndrome	□ ₁	

Form date: ___ / ___ / ___ __ __

Visit #:

Sec	tion 2	2 – Clinical syndrome						ontinued
500		- Cilinean Syrian Sinc						Present
۶	B h. Pr	imary supranuclear palsy (PSP) syndrome						
	8h1. If present, select one: 1 Richardson's syndrome criteria 2 Non-Richardson's							
	8i. Traumatic encephalopathy syndrome							□ ₁
	8j. Corticobasal syndrome (CBS)							□ 1
8	Bk. M	ultiple system atrophy (MSA) syndrome						1
8k1. If present, select one: 1 MSA-predominant cerebellar ataxia (MSA-C) 2 MSA-predominant Parkinsonism (MSA-P) 3 MSA-predominant dysautonomia								
	81. Ot	her (SPECIFY):	<u> </u>					□ 1
9.		ite the source(s) of information used to assign the cli one or more as Yes ; all others will default to No in the	-					
								Yes
9	Pa. Cli	inical information (history, CDR)						□ 1
9	b. Co	ognitive testing						□ ₁
9	9c. Bio	omarkers (MRI, PET, CSF, plasma)						□ 1
Sect	ion 3	- Primary or contributing non-neuro	degene	erative	or non-	CVD conditi	ions	
This m	nust be tion is a	of Section 3 is to identify conditions or disorders tha filled out for those with cognitive or behavioral impart primary, contributing, or non-contributing cause of	airment (i.e the observ	., MCI, MI ved impa	31, dementia irment, bas	a, etc.) Indicate v ed on the clinicia	vhether an's best	a given judgment.
leave		more condition(s) as Present ; if there are no primary ditions blank. All conditions left blank will default to a y.						
		liagnose a disorder, DSM-5-TR criteria require that sational, or other important areas of functioning. For i						
		Condition	Present		Primary	Contributing	Non-c	ontributing
10.	Major	depressive disorder (DSM-5-TR criteria*)		10a.	□ 1	\square_2		\square_3
11.	Other	specified depressive disorder (DSM-5-TR criteria*)		11a.	□ 1	\square_2		□ ₃
12.	Bipola	ar disorder (DSM-5-TR criteria*)	_1	12a.	1	\square_2		□ ₃
13.	Schizo criteri	ophrenia or other psychotic disorder (DSM-5-TR a*)	□ 1	13a.	□ 1	\square_2		□ ₃
14.	14. Anxiety disorder (DSM-5-TR criteria*)						□ 3	
	lf _l	present, (SPECIFY) (check all that apply):						
	14b.	☐ 1 Generalized anxiety disorder						
	14c.							
	14d.	1 Obsessive-compulsive disorder (OCD)						
	14e.	1 Other (SPECIFY):						
15.	Post-t	raumatic stress disorder (PTSD)(DSM-5-TR criteria*)	□ 1	15a.	□ 1	\square_2		□ ₃

Form date: ____ / ___ / ___ __ __ __

Visit #:

rarticipant iD. romi date. / γ visit π.	Participant ID:	Form date:	1	Visit #:
	rarticipant ib.	ronn date.	1	VISIL #

Section 3 – Primary or contributing non-degenerative or non-CVD conditions continued					
Condition	Present		Primary	Contributing	Non-contributing
Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia)	□ 1	16a.	□ 1	□ 2	□ ₃
Delirium (DSM-5-TR criteria*)	□ 1	17a.	□ ₁	\square_2	3
Other psychiatric disorder (DSM-5-TR criteria*)	□ 1	18a.	□ 1	\square_2	3
18b. If present, (SPECIFY):					
Traumatic brain injury (Distinct from TES and CTE, which are documented as a Clinical Syndrome and Etiologic Diagnosis, respectively)	□ 1	19a.	□ 1	□ 2	□ 3
Epilepsy		20a.	□ 1	\square_2	3
Normal-pressure hydrocephalus		21a.	□ ₁	\square_2	3
CNS Neoplasm	□ ₁	22a.	□ 1	\square_2	□ 3
2b. If present, select one: 1 Benign 2 Malignant					
Human immunodeficiency virus (HIV) infection	□ 1	23a.	□ 1	\square_2	3
Post COVID-19 cognitive impairment		24a.	□ 1	\square_2	□ 3
Sleep apnea (i.e., obstructive, central, mixed or complex sleep apnea)	□ 1	25a.	<u> </u>	2	□ 3
Cognitive impairment due to other neurologic, genetic, infectious conditions (<i>not listed above</i>), or systemic disease/medical illness (as indicated on Form A5/D2)	□ 1	26a.	□ 1	□ ₂	\square_3
bb. If present, (SPECIFY):					
Cognitive impairment due to alcohol use or abuse	□ 1	27a.	□ ₁	\square_2	□ 3
Cognitive impairment due to substance use or abuse	□ 1	28a.	□ ₁	\square_2	□ ₃
Cognitive impairment due to medications	□ 1	29a.	□ 1	□ 2	3
Cognitive impairment not otherwise specified (NOS)	□ 1	30a.	□ 1	\square_2	3
Cognitive impairment not otherwise specified (NOS)		31a.	□ ₁	\square_2	3
b. If present, (SPECIFY):					
		32a.	□ ₁	\square_2	3
	Condition Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia) Delirium (DSM-5-TR criteria*) Other psychiatric disorder (DSM-5-TR criteria*) 18b. If present, (SPECIFY):	Condition Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia) Delirium (DSM-5-TR criteria*) Other psychiatric disorder (DSM-5-TR criteria*) 18b. If present, (SPECIFY): Traumatic brain injury (Distinct from TES and CTE, which are documented as a Clinical Syndrome and Etiologic Diagnosis, respectively) Epilepsy Normal-pressure hydrocephalus CNS Neoplasm 2b. If present, select one: 1 Benign 2 Malignant Human immunodeficiency virus (HIV) infection Post COVID-19 cognitive impairment Sleep apnea (i.e., obstructive, central, mixed or complex sleep apnea) Cognitive impairment due to other neurologic, genetic, infectious conditions (not listed above), or systemic disease/medical illness (as indicated on Form A5/D2) 3b. If present, (SPECIFY): Cognitive impairment due to substance use or abuse Cognitive impairment due to medications Cognitive impairment due to medications Cognitive impairment not otherwise specified (NOS) 1 Tognitive impairment not otherwise specified (NOS) 1 Tognitive impairment not otherwise specified (NOS)	Condition Present Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia) 16a. Delirium (DSM-5-TR criteria*) 1 17a. Other psychiatric disorder (DSM-5-TR criteria*) 1 18a. 18b. If present, (SPECIFY): 1 19a. Traumatic brain injury (Distinct from TES and CTE, which are documented as a Clinical Syndrome and Etiologic Diagnosis, respectively) 1 20a. Rormal-pressure hydrocephalus 1 21a. CNS Neoplasm 1 22a. 2b. If present, select one: 1 23a. 1 Benign 2 24a. 2 Malignant 1 25a. Human immunodeficiency virus (HIV) infection 1 23a. Post COVID-19 cognitive impairment 1 24a. Sleep apnea (i.e., obstructive, central, mixed or complex sleep apnea) 1 25a. Cognitive impairment due to other neurologic, genetic, infectious conditions (not listed above), or systemic disease/medical illness (as indicated on Form A5/D2) 26a. 5b. If present, (SPECIFY): 2 Cognitive impairment due to alcohol use or abuse 1 27a. Cognitive impairment due to substance use or abuse 1 29a. Cognitive impairment not otherwise specified (NOS) 1 31a. 1b. If present, (SPECIFY): 2 Cognitive impairment not otherwise specified (NOS) 1 31a. 1b. If present, (SPECIFY): 2 Cognitive impairment not otherwise speci	Condition Present Primary Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia) 1 16a.	Condition

INITIAL VISIT PACKET

UNIFORM DATA SET (UDS) VERSION 4.0



Examiner's

Form D1b: Etiological Diagnosis and Biomarker Support

	PTID:	rom date:/	/	Visit #: initi	ais:			
Langua □1 Er □2 Sp	nglish							
	INSTRUCTIONS : This form is to be completed by the clinician for all participants, including cognitively unimpaired. For additional clarification and examples, see UDS Coding Guidebook for Form D1b . Check only one-participants , see UDS Coding Guidebook for Form D1b . Check only one-participants , see UDS Coding Guidebook for Form D1b . Check only One-participants , see UDS Coding Guidebook for Form D1b . Check only One-participants , see One-participants , see One-participants , see One-participants . See One-participants , see One-participants . See One-par							
	1. Were any biomarker results used to support the current etiological diagnosis? (Consider any biomarker results from any time that may be clinically relevant) 1 Yes (CONTINUE TO QUESTION 2)							
Sect	ion 1 – Biomarkers and imaging							
diagr sourc not ir	Complete this section if any of the following biomarker measures were used to <u>support or exclude</u> a presumed etiological diagnosis, including unimpaired individuals who have biomarker characterization. Please complete the checklist below for each data source available and the related questions for each supporting data. Then complete Section 2: Etiological Diagnosis. This section is not intended to capture actual data values or register sample availability; instead this section's purpose is to record what information was used by the clinician (or at consensus) to inform an etiological diagnosis.							
Flui	ds							
	assessing the etiological diagnosis?	2 Yes, only CSF-ba	-based biomarke QUESTION 3, and ased biomarkers	rs were used SKIP QUESTIONS 4 – 40 were used (SKIP TO QU biomarkers were used	JESTION 4)			
Please use the following questions to indicate the results of the fluid biomarker test(s) used by the clinican (or at consensus) to determine the etiological diagnosis at this visit.								
If a fluid biomarker was used to exclude an etiological diagnosis, select 0=Not consistent . If a fluid biomarker was found to be consistent with a diagnosis, select 1=Yes, consistent . If a fluid biomarker was found to be indeterminate, select 9 . In cases where one or more of the etiologies listed were not assessed using fluid biomarkers, select 8 .								
If a flu	uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent . If a fluid	biomarker was fou	nd to be indeterr					
If a fluction	uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent . If a fluid	biomarker was fou	nd to be indeterrect 8 . Yes,		es where Not			
If a fluctors one consi	uid biomarker was used to exclude an etiological diagnos stent with a diagnosis, select 1=Yes, consistent . If a fluid or more of the etiologies listed were not assessed using flu	biomarker was fou uid biomarkers, sele No,	nd to be indeterrect 8 . Yes,	ninate, select 9 . In cas	es where Not			
If a fluctors one consi	uid biomarker was used to exclude an etiological diagnoss stent with a diagnosis, select 1=Yes, consistent . If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD	biomarker was fou uid biomarkers, sele No, inconsistent	nd to be indeterrect 8. Yes, consistent	Indeterminate	Not assessed			
If a fluconsi one c	uid biomarker was used to exclude an etiological diagnoss stent with a diagnosis, select 1=Yes, consistent . If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD	biomarker was fou uid biomarkers, sele No, inconsistent	rnd to be indeterrect 8. Yes, consistent	Indeterminate	Not assessed			
If a fluconsi one c	uid biomarker was used to exclude an etiological diagnoss stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with other etiology (SPECIEV):	biomarker was fou uid biomarkers, sele No, inconsistent	Yes, consistent	Indeterminate	Not assessed			
If a fluctonsione considerate and a second con	uid biomarker was used to exclude an etiological diagnoss stent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with other etiology (SPECIEV):	biomarker was fou uid biomarkers, sele No, inconsistent 0 0 0	Yes, consistent	Indeterminate	Not assessed			
If a fluctonsione considerate and a second con	uid biomarker was used to exclude an etiological diagnosistent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with LBD Consistent with other etiology (SPECIFY):	biomarker was fou uid biomarkers, sele No, inconsistent 0 0 0 0 No,	rect 8. Yes, consistent 1 1 1 1 1 Yes,	Indeterminate	Not assessed 8 8 8 8 Not			
If a fluctonsione considered as a second a	uid biomarker was used to exclude an etiological diagnosistent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with LBD Consistent with other etiology (SPECIFY):	biomarker was fou aid biomarkers, selected biomarke	Yes, consistent Yes, consistent Yes, consistent Yes, consistent	Indeterminate	Not assessed 8 8 8 8 Not assessed			
If a fluctonsione of a state of the state of	uid biomarker was used to exclude an etiological diagnosistent with a diagnosis, select 1=Yes, consistent. If a fluid or more of the etiologies listed were not assessed using fluood-based biomarkers Consistent with AD Consistent with FTLD Consistent with other etiology (SPECIFY): SF-based biomarkers Consistent with AD Consistent with AD	biomarker was fou uid biomarkers, selected biomarke	Yes, consistent Yes, consistent 1 1 1 Yes, consistent 1 1	Indeterminate 9	Not assessed Not assessed 8 8 Not assessed 8			

Sec	tion	1 – Biomarkers and imaging				(continued
lma	aging						
5.	5. Imaging – Was imaging used for assessing etiological diagnosis? \[\begin{align*}						
Please use the following questions to indicate the results of the imaging used by the clinican (or at consensus) to determine the etiological diagnosis at this visit.							
diag	gnosis,	was used to exclude an etiological diagnosis, select select 1=Yes, consistent . If imaging was found to be not assessed using imaging, select 8 .					
6. P	ET/SF	PECT					
6		acer-based PET - Were tracer-based PET measures u ological diagnosis?	sed in assessing an	1	Yes, resul	TO QUESTION 6b) ts were normal or abr ts were indeterminate	
	If use	d in diagnosis, indicate the results:		No	Yes	Indeterminate	Not assessed
	6a1.	Elevated Amyloid		О	□ ₁	<u> </u>	□8
	6a2.	Elevated tau pathology		О	□ 1	<u> </u>	□8
61	6b. FDG PET - Was FDG PET data or information used to support an etiological diagnosis?		ipport an	☐ 0 No (SKIP TO QUESTION 6c) ☐ 1 Yes, results were normal or abnormal ☐ 2 Yes, results were indeterminate			
			No, inconsistent		es, istent	Indeterminate	Not assessed
	6b1.	Consistent with AD	□ ₀] 1	9	□8
	6b2.	Consistent with FTLD	□ ₀] 1	9	□8
	6b3.	Consistent with LBD	□ ₀] 1	9	□8
	6b4.	Consistent with other etiology (SPECIFY):	□ ₀		□ 1	<u></u> 9	□8
6		opamine Transporter (DAT) Scan - Was DAT Scan da ed to support an etiological diagnosis?	ata or information		Yes, resul	ts were normal or abr ts were indeterminate	
60	su	her tracer-based imaging - Were other tracer-base pport an etiological diagnosis? PECIFY):	d imaging used to	1	Yes, resul	TO QUESTION 7a) ts were normal or abr ts were indeterminate	
			No,		es,	In all at a sure to a t	Not
	6d1.	Consistent with AD	inconsistent		istent	Indeterminate	assessed
	6d2.	Consistent with AD Consistent with FTLD	□ o □ o	_]1 □.	<u></u> 9	∐8 □°
	6d3.	Consistent with LBD	□ ₀		1 1	<u></u> 9	□8 □8
		Consistent with other etiology (SPECIFY):	_				
	6d4.		□ 0		」 1	<u></u> 9	<u></u> 8

_____ Form date: ____ / ___ / ___ __ Visit #: ___

Participant ID:			Form dat	te:	/ / .			Visit #:	
Secti	on 1 –	Biomar	kers and imaging						continued
7. Structural Imaging									
7a. Structural Imaging (i.e., MRI or CT) – Was structural information used to support an etiological diagram				maging data or	□ 0 No (SKIP TO QUESTION 8) □ 1 Yes, results were normal or abnormal □ 2 Yes, results were indeterminate				
				No, inconsistent	Yes, consistent		Indeterminate	Not assessed	
78	a1. At	Atrophy pattern consistent with AD		□ ₀			<u></u> 9	□8	
78	a2. At	Atrophy pattern consistent with FTLD		□ ₀			<u></u> 9	8	
78	a3. Co	Consistent with Cerebrovascular disease (CVD)		□ ₀] 1	<u></u> 9	□ 8	
	lf t	f there is evidence for CVD on imaging, indicate the findings:			e findings:	No	Yes	Indeterminate	Not assessed
	7a3a.	3a. Large vessel infarct(s)				О	□ ₁	<u>9</u>	□8
	7a3b. Lacunar ir		infarct(s)			О	□ 1	<u></u> 9	□8
7a3c.		Macrohemorrhage(s)				О		<u></u> 9	□ 8
7a3d.		Microhe	Microhemorrhage(s)			\square_0	□ ₁	<u>9</u>	□8
	7a3e.	3e. White matter hyperintensity				О	□ 1	<u></u> 9	□8
7a3e1. If Yes, choose the severity: 1 Moderate white-matter hyperintensity (CHS score 5-6) 2 Extensive white-matter hyperintensity (CHS score 7-8+)									
Other biomarker modalities (e.g., tissues, skin, retinal imaging, etc.)									
Please use the following questions to indicate the results of any additional biomarker modalities used by the clinician (or at consensus) to support the etiological diagnosis at this visit.								r at	
If a biomarker modality was used to exclude an etiological diagnosis, select 0=Not consistent . If a biomarker modality was found to be consistent with a diagnosis, select 1=Yes, consistent . If a biomarker was found to be indeterminate, select 9 . In cases where one or more of the etiologies listed were not assessed using a biomarker modality, select 8 .									
 Other biomarker modality - Was another biomarker mo support an etiological diagnosis? (SPECIFY): 				arker mod	dality used to	1	□ 0 No (SKIP TO QUESTION 11) □ 1 Yes, results were normal or abnormal □ 2 Yes, results were indeterminate		
					No, inconsistent		es, istent	Indeterminate	Not assessed
8a.	Consis	stent with	AD		\Box_0		1	<u> </u>	□8
8b.	Bb. Consistent with FTLD			О		1	<u></u> 9	8	
8c.	Consistent with LBD			□ ₀		1	<u></u> 9	□ 8	
8d.	Consis	stent with	other etiology (SPECIFY):		О		□ 1	<u> </u>	□8

9. O	on 1 – Biomarkers and imaging ther biomarker modality - Was another biomarker mod upport an etiological diagnosis? PECIFY):	dality used to	o No (SKIP TO QUESTION 11) 1 Yes, results were normal or abnormal 2 Yes, results were indeterminate			
		No, inconsistent	Yes, consistent	Indeterminate	Not assessed	
9a.	Consistent with AD	□ ₀	□ 1	<u></u> 9	□8	
9b.	Consistent with FTLD	□ ₀	□ 1	□ 9	□8	
9c.	Consistent with LBD	О	□ 1	<u></u> 9	□8	
9d.	Consistent with other etiology (SPECIFY):	О	□ 1	<u></u> 9	□8	
 Other biomarker modality - Was another biomarker mod support an etiological diagnosis? (SPECIFY): 		dality used to	☐ 0 No (SKIP TO QUESTION 11) ☐ 1 Yes, results were normal or abnormal ☐ 2 Yes, results were indeterminate			
		No, inconsistent	Yes, consistent	Indeterminate	Not assessed	
10a.	Consistent with AD	□ ₀	□ 1	□ 9	□ 8	
10b.	Consistent with FTLD	□ ₀	□ 1	9	□8	
	Consistent with LBD	□ ₀	□ 1	<u></u> 9	8	
10c.						
10c. 10d.	Consistent with other etiology (SPECIFY):	□ ₀	□ 1	<u></u> 9	8	
10d.	Consistent with other etiology (SPECIFY): ortive genetics	□o	1	<u></u> 9	□ 8	

Participant ID:	Form date:	/	/	Visit #:

Section 2 - Etiological diagnoses

Using all the available data (i.e. clinical, cognitive, biomarker, etc) please provide an etiological diagnosis. For those with no biomarker data, enter a **presumed** etiological diagnosis.

<u>Must be filled out for all participants</u>. Indicate whether a given condition is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician's best judgment. Select one or more etiological diagnoses from questions (*below*) as **Present**; all others will default to **Absent** in the NACC database. *Only one diagnosis should be selected as* **1** = **Primary**.

<u>For unimpaired participants:</u> Proceed using your center's diagnostic philosophy to determine whether the etiology is present and primary, contributing, or non-contributing or leave the checkboxes blank.

	Etiological Diagnoses	Present		Primary	Contributing	Non- contributing
12.	Alzheimer's disease	□ 1	12a.	□ 1	2	□ 3
13.	Lewy body disease	□ 1	13a.	□ 1	_2	□ 3
14.	Frontotemporal lobar degeneration (FTLD)	□ 1				
	If present , select all that apply:					
	14a. Progressive supranuclear palsy (PSP)	□ ₁	14a1.	□ 1	\square_2	□3
	14b. Corticobasal degeneration (CBD)	□ ₁	14b1.	□ 1	\square_2	□3
	14c. FTLD with motor neuron disease	□ 1	14c1.	□ 1	\square_2	□ 3
	14d. FTLD - not otherwise specified (NOS)	□ 1	14d1.	□ 1	\square_2	□ 3
	14e. If FTLD (QUESTION 14) is present, specify FTLD s 1 Tauopathy 2 TDP-43 proteinopathy 3 Other (SPECIFY): 9 Unknown	,				
15.	Vascular brain injury (based on clinical and imaging evidence according to your Center's standards)	□ 1	15a.	□ 1	□2	□ 3
16.	Multiple system atrophy	□ 1	16a.	□ 1	\square_2	3
17.	Chronic traumatic encephalopathy (CTE)	□ 1	17a.	□ 1	\square_2	□3
	17b. If CTE (QUESTION 17) is present, specify certaint 1 Suggestive CTE 2 Possible CTE 3 Probable CTE	y:				
18.	Down syndrome	□ 1	18a.	□ 1	_2	3
19.	Huntington's disease	□ 1	19a.	□ 1	_2	□ 3
20.	Prion disease (CJD, other)	□ 1	20a.	□ 1	_2	3
21.	Cerebral amyloid angiopathy	□ 1	21a.	□ 1	_2	□ 3
22.	LATE: Limbic-predominant age-related TDP-43 encephalopathy	□ ₁	22a.	□ 1	□ ₂	□ 3
23.	Other (SPECIFY):	□ 1	23a.	□ 1	2	3

NATIONAL ALZHEIMER'S COORDINATING CENTER <u>naccmail@uw.edu</u> naccdata.org